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 „Carbohydrates, even nowadays, form a typical field 
for discovering new knowledge“ 
 
Thisbe K. Lindhorst
 1 
Abstract 
In this work, potential intermediates for antiviral and antitumor agents were successfully 
synthesized. Because of the advantages and enormous biologic activity of the glycosides/nu-
cleosides and metal-based drugs, according to the previous research, the combination of both 
types was investigated. Hence, this thesis is focused on the development of the 2-deoxy-D-
ribofuranose analogues, due to the similarity with DNA building blocks, with diamine moi-
eties that should be able to form metal complexes similar to cisplatin. This thesis deals with 
the synthesis and characterization of C-nucleoside analogues of D-ribose. By optimizing the 
reaction conditions, the synthesis of the β-allyl-C-glycoside of the 2-deoxy-D-ribofuranose 
were improved and, as a result, excellent yields were achieved. The regioselectivety and 
correct stereochemistry of the C-allyl residue introduced, have been analytically investigated 
and confirmed. In addition, we have succeeded in obtaining several 2-deoxy-D-ribofuranose 
derivatives with ethylenediamine group on a spacer with one or three carbon atoms to the 
sugar moiety. Preliminary tests for the synthesis of carbohydrate-metal-complexes were 
done. Furthermore, several potentially biologically active compounds were obtained. The 
compounds are at present widely investigated as ligands for cis-platinum complexes and for 
other metal complexes. 
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1 Introduction 
1.1 Carbohydrates 
Carbohydrates are one of the four most important classes of biomolecules, besides proteins, 
nucleic acids and lipids. The monosaccharides form the fundamental building blocks for 
polysaccharides, according to the number of their subunits divided into mono-, oligo- and 
polysaccharides. It is estimated that over 1011 tons of carbon dioxide are absorbed by photo-
synthesis each year. This carbon dioxide is reduced by light energy to form carbohydrates. 
The greatest part of naturally occurring carbohydrates are not free monosaccharides, but their 
condensation products. One of the most common condensed products is starch, accumulating 
in chloroplasts during day light and is then used by the plant during the night as an energy 
source. Likewise, for humans and animals carbohydrates are the important energy sources, 
which also serve for the storage of energy (glycogen, ADP/ATP, NAD+/NADH).[1] In the 
human body, simple sugar such as sucrose and glucose are easily absorbed and metabolized 
to give energy and CO2. Composite carbohydrates can not be easily absorbed, either they are 
partly biodegraded by enzymatic processes.[2] Furthermore, carbohydrates are essential com-
ponents of nucleosides of DNA and RNA and as building blocks of it. By covalent linking 
of oligomers or polymeric carbohydrates with lipids or proteins glycolipids and glycopro-
teins form. They are found for example in cell membranes, where they are involved in many 
cellular processes such as cell-cell recognition, cellular transport and cell adhesion.[3] 
1.2 C-glycosides 
The replacement of the anomeric oxygen of a sugar by a carbon atom of some heterocycle, 
results in a C-glycoside. A nucleoside is a specific form of glycosides, where the heterocycle 
is one of the nucleobase and a sugar is a ribofuranose or 2-deoxy-ribofuranose. The C-gly-
cosides have specific chemical reactivities, like absent anomeric effect and stability to the 
acid hydrolysis and enzymatic attacks. Furthermore, in tumor cells, virus host cells and bac-
teria, a rapid metabolism is observed, modified carbohydrates, like glycoside or nucleoside 
analogues, can greatly influence the DNA transcription and metabolic processes as interfer-
ing factors, leading to cell necrosis. In recent years, several naturally occurring C-glycosides 
(Figure 1) with significant biological potentials such as antibacterial, antiviral, anti-HIV and 
anti-tumor effects have been isolated.[4] 
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The broad spectrum of biological activities of naturally occurring glycosides and nucleoside 
analogues is one of the reasons why these substances have been used as the lead structures 
for the synthesis of drugs with antibacterial, antiviral, cancerostatical and fungicidal proper-
ties.[5],[6] Some known synthetic compounds with important biological properties and medi-
cal relevance are shown in Figure 2.  
The AZT or 3ˈ-azido -3ˈ-deoxythymidine is one of the most applied drugs to treat HIV.[7] 
Acyclovir and its derivatives are used as a drug against most species of the herpes virus 
family.[8] Ribavirin has a broad spectrum of applications and is used against DNA and RNA 
viruses such as hepatitis C virus, herpes virus, influenza virus and viral hemorrhagic fe-
vers.[9] Three different strategies are known to synthesize glycosides and nucleoside ana-
logues. The first variant is the modification of the naturally occurring glycosides and nucle-
osides; the second variant is the modification of already existing synthetically produced mol-
ecules. The third variant envisages a total synthesis of simple molecules, in which carbohy-
drates are generally not used.[10] The glycosides or nucleosides analogs can be accomplished 
by rearrangement of the heterocycle or carbohydrate moiety, as well as by modification of 
the linkage between the monosaccharide and the heterocycle. The third variant involves a 
structural change by the incorporation of a methylene group or an alkylidene chain. These 
structures are referred to homo-C-glycoside analogs or bridged-/(spacer)-C-glycoside ana-
logs.[11] 
Showdomycin 
 
Formycin 
 
Pyrazofurin 
 Figure 1. Naturally occurring C-glycosides. 
AZT 
Retrovir® 
 
Acyclovir 
Aciclovir®, Zovirax® etc 
 
 
Ribavirin 
Copegus®, Rebetol®, etc 
 
Figure 2. Synthetic nucleoside analogues with important medical relevance. 
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1.3 Medical relevant drugs, containing transition metals 
The use of metal-based drugs in medicine has a long history. However, the most important 
and known metal containing drug is the cisplatin. In 1964, B. Rosenberg, a professor of 
biophysics at Michigan State University, measured the influence of electric fields on Esch-
erichia coli cell growth. In this experiment, as shown in Figure 3, platinum electrodes and a 
nutrient medium of glucose, MgCl2 and NH4Cl were used. 
This experiment has showed that the cell division of E. coli was inhibited, resulting the for-
mation of the long filamentous bacterial cells.[12] Over the following years, it was proved 
that the use of platinum electrodes and NH4Cl has led to the electrochemical synthesis of 
platinum compounds, such as the cis-diamminetetrachloridoplatin(IV), cis-(NH3)2PtCl4, and 
the cis-diamminedichloridoplatinum(II), cis-(NH3)2PtCl2, also known as cisplatin, having 
the growth inhibitory effect. The most effective cis-(NH3)2PtCl2 species is a square-planar 
Pt2+ complex containing two chlorido and two ammonia ligands in cis position (Figure 4), 
giving the compound its trivial name. 
The biological activity of cisplatin is not limited just to bacteria. Generally, strong cytostatic 
properties against many other cells were observed. From a medical point of view, this phe-
nomenon is of particular interest for fighting rapidly growing tumor cells. After successful 
Escherichia coli 
Pt-electrodes 
Glucose, MgCl2, NH4Cl 
 
῀ 
Figure 3. The experiment of professor Rosenberg. 
cis-(NH3)2PtCl2 
„Cisplatin“ 
cis-(NH3)2PtCl4 
Figure 4. Platinum compounds, inhibiting the growth of bacteria. 
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application of cisplatin on animals,[13] medical studies on humans were done, showing the 
effectivity against the variety of the cell lines of cancer.[14] 
Table 1. Clinical activity of the cisplatin as single agent against 
various human tumors.[14] 
tumor type 
number of responders related 
to the total of treated patients 
genito-urinary tumors  
testicular tumors 58% 
prostatic carcinomas 30% 
penile carcinomas 53% 
carcinomas of the head and neck 44% 
skin tumors 24% 
brain tumors 40% 
bronchogenic tumors 15% 
gastrointestinal tumors  
gastric carcinomas 21% 
esophageal carcinomas 20% 
lymphomas 28% 
The actual anti-tumor effect mechanism could only be explored by comparing many similar 
platinum complexes. The mechanism of action of cis-platinum has been much speculated 
and various mechanisms proposed. The most likely variant was the covalent binding of cis-
platinum to the DNA in the nucleus. Several types of DNA-platinum-adducts are proposed 
to be formed. The most stable binding results were found between platinum and the N-7 
positions of two guanine moieties in the DNA, both interstrand and intrastrand. Neverthe-
less, the interaction between cisplatin with a single guanine base, between cisplatin and gua-
nine proteine crosslink and in some cases the cisplatin-adenine-guanine-intrastrand crosslink 
were observed. Which type of adduct is most responsible for the cytotoxic effect of cisplatin 
has never been fully established. This interaction between platinum and DNA leads to inhi-
bition of the DNA replication, resulting cell death, especially of rapidly dividing cells, like 
the tumor cells.[15] 
The discovery of a second and third generation of cisplatin complexes has helped to reduce 
some side effects and to achieve better pharmacokinetic properties. The second and third 
generation of cisplatin drugs are platinum complexes with further ligands,[16] where, for ex-
ample, the dichloro ligands were replaced by a 1,1-cyclobutadiene carboxylate group (car-
  6 
boplatin). Carboplatin, compared to cisplatin can be applied in higher doses with lower tox-
icity. In case of oxaliplatin, the two ammonia groups on the platinum atom were replaced by 
a 1,2-diaminocyclohexane group, resulting in lower reactivity and thereby reducing toxicity 
(Figure 5).[17]  
In the following years, other transition metals (palladium, rhodium, iridium, ruthenium, etc) 
were investigated for their biological activities and cytostatic properties.[18] The other potent 
metal complexes with high cytostatic properties are the ruthenium-based drugs.[19] 
Moreover, increasing research on metal-carbohydrate complexes over the last 20 years 
shows their enormous importance in many bioorganic processes in different organisms. For 
example, platinum-carbohydrate complexes with excellent cytostatic activity.  
In the Figure 6, one of the biologically active platinum-carbohydrate complexes is shown. 
The galactose-Pt(II) complex has showed an increased therapeutic index by over 30-fold, 
compared to cisplatin and oxaliplatin, offering improved cytotoxicity against human colon 
and lung cancer cell lines.[20]   
Oxaliplatin Carboplatin 
Figure 5. Second generation of cisplatin complexes. 
Galactose-Pt(II) complex 
Figure 6. Galactose-Pt(II) complex with significant tumor cytotoxicity. 
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1.4 The aim of the thesis 
The rapidly increasing number of new diseases and tumor lines in modern society requires 
increased research in this field. Therefore, the aim of this work was to achieve potential 
intermediates for antiviral and antitumor agents. Because of the advantages and enormous 
biological activity of glycoside and metal-based drugs, according to previous research, the 
combination of both types was desirable. Moreover, the combination of carbohydrate moie-
ties and metal complexes are supposed to be more effective and less toxic, than the particular 
one. Hence, we focused on the development of 2-deoxy-D-ribofuranose analogues, due to 
the similarity with the DNA building blocks, with diamine moieties that should be able to 
form the metal complexes similar to cisplatin. 
For the present work, the strategy of synthesis of the β-allyl-C-glycoside of the 2-deoxy-D-
ribofuranose were used, previously mentioned by Dr. Heike Otero Martinez (née Wächtler) 
in her dissertation 2008 [21], Dr. Dilver Pena Fũentes in his dissertation 2012 [22] and in the 
following publications [23], [24]. The first step was to combine the preliminary research for the 
synthesis of the β-allyl-C-glycoside of the 2-deoxy-D-ribofuranose, as well as the optimiza-
tion, validation and verification of the synthetic pathway. 
The next step was to convert the double bond of the allyl group into a diamino group. Fur-
thermore, we wanted to examine the possibilities to arrange the platinum at different dis-
tances to the furan ring, achieving in this way more flexibility of the molecule. 
The preliminary verification of the reaction of the 2-deoxy-D-ribofuranose analogues with 
diamine moieties with platinum was also required. Thus, applying the cis-platinum-glyco-
side analogue complex could lead not only to better cytostatic results, but the combination 
of an active metal complex with a ligand, which has its own biological activity, could also 
lead to entirely new pharmacological effects. 
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2 Results & Discussion 
2.1  Synthesis of the β-C-allylglucoside of the 2-deoxy-D-ribofuranose 
2.1.1 Synthesis of the D-ribofuranose derivative 2 suitable for the preparation of the 
C-allylglucoside 
Starting with commercially available D-ribose, the first aim was to synthesize the β-C-gly-
coside in kinetically preferred form of the D-ribofuranose. In aqueous solution, D-ribose ex-
ists as a isomers mixture: α- and β-ribopyranose as a six-membered ring and α- and β-ribo-
furanose as a five-membered ring and in less than 0.1% in two acyclic form (hydrate and 
aldehyde).[25] Therefore, simple acetylation of D-ribose gave a mixture of different acetylated 
products, preferentially with the ribopyranose as a thermodynamically stable product.[26] 
Making the purification and isolation of the desired β-ribofuranose from this mixture highly 
sophisticated. That’s why, the synthesis pathway presented in this work, to achieve the 2-
deoxy-D-ribofuranose, simplified the whole procedure already from the first step. 
Regarding the Scheme 1, the D-ribose reacted with dry acetone in the presence of catalytic 
amounts of sulfuric acid as an activator to give compound 1.[27] The quality of the acetone 
was found to be crucial.[28] The addition of the activated acetone to the hydroxyl groups 
forms the hemiacetal firstly, which reacts with the vicinal hydroxyl group to form the five-
membered ring.[29] The isopropylidene protective group on the carbon atoms C-2ˈ and C-3ˈ 
of the sugar ring1 fixed the D-ribose in its furanose form. The yield of compound 1a amounts 
                                                 
1   The atom numbering of carbon and hydrogen atoms of the ribofuranose ring refers to the standard number-
ing of pentoses and may differ from the IUPAC numbering used in naming of the molecule. The atom 
numbering used here is obviously shown in the experimental section for each compound respectively. 
 1a 
i: dry acetone, cat. H2SO4, 2 h, rt; ii: dry pyridine, Ac2O, 15 h, rt. 
1b
b 
i 
ii 
 
Scheme 1. Synthesis of compound 2. 
 1a 
 1a 
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to 87%. To achieve a good yield, it is significant to add 1% v/v triethylamine to the eluent 
by the chromatographical purification. Furthermore, the pyranose form derivative 1b, con-
taining two isopropylidene groups on the carbon atoms C-1ˈ and C-2ˈ, together with C-3ˈ 
and C-4ˈ, was isolated by flash chromatography and characterized, yielding 0.4%.[30],[31] In 
the next step, the acetylation was done. Therefore, the purified compound 1a was treated 
with dry pyridine and freshly distilled acetic anhydride at 0 °C.[32] We have found, that the 
usage of the freshly distilled acetic anhydride could increase the yield considerably. The 
reaction mixture was stirred over night at room temperature. Next addition of methanol re-
moved excess of Ac2O from the reaction mixture. After work up and flash chromatography, 
product 2 was achieved in 93% yield as a colorless syrup. In 1H-NMR, four characteristic 
signals of the methyl groups were found: for two methyl groups of the isopropylidene group 
at 1.34 ppm and 1.50 ppm and for two methyl groups of the acetyl groups at 2.06 ppm and 
2.09 ppm, which indicates together with other analyses the desired diacetylated compound 
2. 
2.1.2 Synthesis of the C-allylglucoside of D-ribofuranose 
Diacetate 2 was converted into the C-furanosyl compound 3 by treatment with zinc bromide 
and allyltrimethylsilane (AllTMS) [33] in MeNO2 as a solvent 
[23],[24]. After several experi-
ments we have found that the freshness and dryness of the ZnBr2 together with a quick ad-
dition of ZnBr2 to the reaction mixture, played the main role in achieving a good yield.
[34] 
The work up of this reaction was also very tricky, while the extraction, the intense shaking 
could led to the emulsion, which was difficult to separate, causing the yield loss. To prevent 
an emulsion layer the vigorously shaking of the mixture must be avoided and the ratio of the 
organic and aqueously phase should be complied! 
i: ZnBr2, AllTMS, MeNO2, 0 °C → rt, under an argon atmosphere. 
3 
 
2 
 
i 
 
Scheme 2. Synthesis of compound 3. 
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In this reaction, zinc bromide has acted as a lewis acid, activating the acetyl group at the 
anomeric center, increasing its aptitude the readiness of the acetyl group to leave its position 
(Scheme 3). This allowed the nucleophilic addition of the allyltrimethylsilane at the anomeric 
center of the furane ring. The silyl group was attacked by the free bromide ion and removed, 
forming the terminal double bond on the carbon chain.  
The advantageous location of one of the methyl groups of isopropylidene caused by steric 
hindrance, benefiting the formation of the β-product and preventing attack of the nucleophile 
at the α-position, giving compound 3 with a α/β ratio of 1:6. After appropriate purification, 
the desired pure β-C-allylribofuranose 3 was isolated as colorless syrup by flash chromatog-
raphy in a yield of 78%. The structure of β-compound was confirmed via NMR, especially, 
nuclear overhauser enhancement and exchange spectroscopy (NOESY). 
i: ZnBr2, AllTMS, MeNO2, 0 °C → rt, under an argon atmosphere. 
i 
 
Scheme 3. Proposed reaction mechanism of the synthesis of C-allylglucoside 3. 
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2.1.3 Synthesis of the 2-deoxy-D-ribofuranose derivative 7 
The synthesis pathway to produce the 2-deoxy-D-ribofuranose derivative 7 is shown in the 
Scheme 4. 
Because of the two different kinds of protecting groups of the compound 3, there are some 
possibilities for further syntheses of various intermediates. However, for our purposes, all 
protecting groups except the allyl group must be cleaved. It is well known, that the acetals 
are hydrolysed by dilute aqueous acid. [29] Treatment of compound 3 with hydrogen chloride 
1 M in ethanol for 2 d at room temperature hydrolysed advantageously not only the isoprop-
ylidene group, but also the acetyl group, giving the unprotected species 4 in a yield of 85% 
as a colorless syrup. After storage of the syrup in refrigerator, a colorless amorphous solid 
was formed. Unfortunately, the crystallisation of compound 4 for X-ray crystallographic 
analysis was unsuccessful. Nevertheless, the varied analytical data confirmed the structure 
of the unprotected species with a very high probability. 
The crucial challenge of the next step was simultaneous protection of the  3ˈ- and 5ˈ-posi-
tions of the ribofuranose ring. This problem was previously solved by Markiewicz, working 
with tetraisopropyldisiloxane.[36] For our purpose, the tetraisopropyldisiloxane group was 
also absolutely appropriate. The treatment of deprotected compound 4 with 1,3-dichloro-
1,1,3,3-tetraisopropyldisiloxane (TIPDSCl) and imidazole, as an acid scavenger, in dry DMF 
[37] at 0°C avoided regioisomers and afforded compound 5 in a yield of 85%. 
i: 1.0 M HCl, ethanol, 2 d, rt, ii: TIPDSCl, imidazole, DMF, 1 h, 0 °C,  iii: I2, Ph3P, imidazole, 
dry toluene, 2x5 h, reflux, iv: Bu3SnH, AIBN, dry toluene, 4 h, reflux. 
3 
7 6 
5 4 
i 
iv 
iii 
ii 
Scheme 4. Synthesis of the 2-deoxy-D-ribofuranose derivative 7. 
  12 
Previous experiments for deoxygenation of carbohydrate-type compounds were done under 
noxious conditions (phosgene). They were not chemospecific for the 2ˈ-position and ren-
dered byproducts.[38],[39] A general procedure for the efficient deoxygenation of secondary 
alcohols at ribonucleosides was developed by M. J. Bobins, J. S. Wilson and F. Hansske [40] 
using phenoxythiocarbonyl for further radical-based reduction. The iodination procedure in 
carbohydrates for converting a hydroxyl group into an iodo group was developed by Garegg 
et al. [41]. The inversion of the substituents on the 2ˈ-position of the ring is due to the redox-
mediated nucleophilic SN2-reaction (mukaiyama redox condensation), where the carbon C-
2ˈ containing the hydroxyl group had the (S)-configuration and with the iodine became (R)-
configured. Triphenylphosphine oxide resulting from the procedure of iodination was com-
pletely removed from the system by flash chromatography with relatively nonpolar eluent 
(petroleum ether – EtOAc 100:1) giving 6 in 95% yield. That allowed the optimal radical-
based reduction under standard free-radical conditions with tri-n-butyltin hydride, catalysed 
by azobisisobutyronitrile (AIBN) previously applied by Gimisis et al.[42] It is well known, 
that the reactions, using tri-n-butyltin hydride as a reactant, are leading to the formation of 
tin salts as byproducts, which are hard to remove. Therefore, for the removal of the tin spe-
cies from the reaction mixture, the work of P. Kocienski and C. Pant was applied.[43] In this 
processing variant, the highly insoluble tin salts were achieved by treatment of the reaction 
mixture with aqueous 10% potassium fluoride solution and removed by aqueous work up, 
followed by flash chromatography. The use of this work up procedure has led to the easy 
isolation of product 7 in a yield of 89% as a colorless syrup. The deoxygenation of the posi-
tion 2ˈ was confirmed via elemental analysis and mass spectra. The 1H-NMR showed two 
signals, each with one proton for the H-2ˈa at 1.78–1.89 ppm and for the H-2ˈb at 1.97–
2.07 ppm, instead of a multiplet at 4.24–4.28 ppm, presented one proton of the H-2ˈ of com-
pound 6. Treatment of compound 7 with tetrabutylammonium fluoride trihydrate (TBAF) in 
dry acetone [44] provided compound 8 in a good yield (Scheme 5). The total yield of the com-
plete reaction pathway was markedly improved to 54%, compared to the previously reported 
34%.[23],[34],[35]  
i: TBAF, dry acetone, 1.5 h, rt. 
. 
8 7 
i 
. 
Scheme 5. Cleavage of the silyl protecting group. 
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Furthermore, it was confirmed that the protocol for the synthesis of compounds 1–8 also 
could be used for large-scale work. The synthetic pathway for improved synthesis of all 
previous compounds until the 2-deoxy-D-ribofuranose derivates 7 and 8 was evaluated and 
verified by a few renowed scientists and it was successfully published in the book Carbohy-
drate Chemistry: Proven Synthetic Methods, Vol. 4.[34],[ 35] 
The hydroxyl groups of compound 8 in positions C-3ˈ and C-5ˈ can be easily used for further 
transformation, some of them are shown in the Scheme 6.  
The preliminary experiments, to confirm this statement, showed that an ether, for example 
Benzyl,[22] or an ester group, like Benzoyl (unpublished)2, or 4,4ˈ-dimethoxytrityl group on 
3ˈ and phosphoramidite derivative an 5ˈ, which will be mentioned later, and other substitu-
ents can be introduced on this positions. Different protecting groups could be chosen, de-
pending on the further reaction requirements, with high acid or base lability or even with the 
different reactivity on both positions. 
                                                 
2    We introduced benzoyl groups the same way as by the introduction of pivaloyl. The work-up procedure 
was not enough for the benzoyl, so the spectra of NMR showed residues of benzoyl chloride together with 
the desired product. So an improved work up procedure is required. 
8 
i 
ii 
iii, iv 
i: Benzyl bromide, NaH 60% in oil, dry DMF, 6 h, rt, ii: Benzoyl chloride, DMAP, pyridine, 15 h, rt,  
iii: 4,4ˈ-dimethoxytrityl chloride, NEt3, dry DMF, 24 h, rt, iv: 2-cyanoethyl N,N-diisopropyl-chloro-
phosphoramidite, diisopropylethylamine, dry CH2Cl2, 3 h, rt. 
Scheme 6. Some possible further protections of positions C-3ˈ and C-5ˈ. 
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2.2 Synthesis of the β- allyl-C-glucoside of the 2-desoxy-D-ribofuranose 
with ethylenediamine moieties 
2.2.1 Synthesis of the primary alcohol via hydroboration-oxidation reaction 
Here, we converted the allyl group of compound 7 into a primary alcohol as an intermediate 
stage (Scheme 7). For our purpose, the hydroxyl group was very stable. Hence, it was trans-
formed into mesyl compound 10, which reacted smoothly in the following steps.  
The transformation of the allyl group of the 2-deoxy-D-ribofuranose derivates 7 into the ter-
minal alcohol 9a occurred over a hydroboration–oxidation reaction. Therefore, olefin 7 was 
treated with a 1.0 M borane tetrahydrofuran complex solution in dry THF and the mixture 
was stirred intensively for 3 h at 0 °C.[45] The BH3 bound regioselectively to the less hindered 
carbon atom of the olefin. A 4-electron-4-center transition state with a following addition of 
the B-H fragment on the double bond was formed via syn-addition (Scheme 8). This process 
was repeated twice more, until the triple substituted borane is formed. After that, the mixture 
of aqueously sodium hydroxide solution 3 M and 30% hydrogen peroxide was very cau-
tiously added to the stirred reaction mixture. The electron poor boron atom was attacked by 
the electron rich hydroperoxide ion by formation of the peroxydic boranate with very weak 
O-O bond. The following rearrangement causes the elimination of a hydroxide ion by reten-
tion of the configuration. This process was repeated until all three substituents have migrated 
to the oxygen atoms and a boric-acid ester was formed. The boric-acid ester was hydrolysed 
with a base, forming mostly the anti-Markovnikov product - primary alcohol 9a.[46] We have 
also isolated the Markovnikov product 9b in a yield of approx. 5%. By varying reaction 
conditions the Markovnikov product could be obtained in a yield up to 19%. The byproduct 
9b was easily separated by column chromatography. 
i: BH3*THF, dry THF, 3 h, 0 °C. 
. 
9a 
anti-Markovnikov  
product 
i 
. 
+ 
. 9b 
Markovnikov  
product 
Scheme 7. Synthesis of the primary alcohol 9a. 
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2.2.2 Synthesis of the important intermediate 10 and further reactions 
Related to the general knowledge about the stability of primary hydroxyl groups for substi-
tution reactions, the primary alcohol is relatively stable, so another leaving group was nec-
essary. Mesylation of the primary alcohol led to a convenient leaving group for further nu-
cleophilic substitution reactions. For this purpose, the variant of Kornilov et al. was applied 
[47] to achieve intermediate 10. Therefore compound 9 was treated with methansulfonyl chlo-
ride (MsCl) in dry CH2Cl2 with addition of triethylamine. Thus, after a short reaction time 
Scheme 8. Proposed mechanism of hydroboration-oxidation reaction. 
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of 20 min and after the corresponding work up, the mesylated compound 10 was obtained in 
an excellent yield of 93% (Scheme 9).  
In the following step, we have made a series of attempts, treating the intermediate 10 with 
several nucleophiles to obtain compounds 11-15 (Scheme 10). 
i: MsCl, NEt3, dry CH2Cl2, 20 min, 0 °C. 
. 
10 9 
i 
. 
Scheme 9. Synthesis of the mesylated compound 10. 
i: Morpholine, dry methanol, 6 d, rt; ii: Cyclohexylamine, dry methanol, 6 d, rt; iii: Aniline, dry metha-
nol, 5 d, rt; iv: 2-Aminobenzimidazole, dry methanol, 10 d, rt; 
v: Ethane-1,2-diamine, dry methanol, 22 h, rt. 
10 
11 
i 
. 
ii 
. 
iii 
. 
iv 
. 
v 
. 
12 
13 
14 
15 
Scheme 10. Synthesis of compounds 11-15. 
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The substitution reactions of mesylate 10, leading to products 11-15 were carried out in dry 
methanol for different reaction times, until the reactions were completed. All experiments 
were carried out at room temperature. The differences in the reaction time, 22 h to 10 d, can 
be explained by the different solubility of the reactants in dry methanol. Probably, the choice 
of other solvents or a reaction temperature could make the substitution faster, but it was not 
the purpose of this work. The reactants were selected due to their reported biological activi-
ties. For example, morpholines have showed anaesthetic, antifungal [48] and antiviral [49] 
properties, even DNA protein kinase inhibitory activity.[50] Bhakta et al. scanned the activity 
of several substituted pyrroles against mycobacterium tuberculosis. Cyclohexanamine sub-
stituted pyrrole showed low eukaryotic cell toxicity with highly antitubercular activity on M. 
smegmatis, M. bovis and M. aurum mycobacterial strains and against multidrug-resistant 
clinical isolates.[51] Aniline derivatives were tested as highly potent and nontoxic inhibitors 
of breast cancer resistance protein (ABCG2).[52] The substituted ethylenediamines were thor-
oughly investigated in their effects. Acting as classic bidentate ligand, ethylenediamine are 
well known in catalysis. Also, the medical effect of ethylenediamine substituted molecules 
is very eclectic. For example, Tiwari et al. have found that substituted ethylenediamine 
showed very good performance against filariasis3.[53] Therefore, important ligand 15 was 
prepared by dissolving compound 10 in dry methanol and reacted it with ethane-1,2-diamine 
at room temperature. After stirring for 22 h, product 15 was isolated as a light-yellow syrup 
in an excellent yield of 95% and it was characterized analytically. The absence of sulfur and 
the presence of nitrogen was confirmed by elemental analysis.  
To deprotect 15, this compound was dissolved in dry acetone and treated with tetra-n-bu-
tylammonium fluoride trihydrate (TBAF) in dry acetone.[44] The chromatographic purifica-
tion of compound 16 was very laborious because of its high polarity. The use of a very short 
chromatographical column and the eluent, which contained 1% triethylamine, is highly rec-
ommended for the purification. In 1H NMR and 13C NMR spectra, there were no peaks of 
the tetradiisopropyldisiloxane detected, indicating a complete elimination of the silyl pro-
tecting group. Product 16 was isolated in an excellent yield of 90% and characterized ex-
haustively (Scheme 11). 
                                                 
3  Filariasis is a parasitic disease transmitted by mosquitoes. It is caused by filarial worms living almost ex-
clusively in humans, lodged in the lymphatic system.  
i: TBAF, dry acetone, 1.5 h, rt. 
. 
16 15 
i 
. 
Scheme 11. Deprotection of compound 15. 
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2.2.3 Synthesis of the primary amine and Schiff base 
The primary amines give the great opportunity for further reactions, even acting as a leaving 
group for the preparation of N-nucleosides.[54],[21] The mesyl group gave an excellent oppor-
tunity for the transformation into the primary amine. We have modified the pathway used 
by Kornilov et al. to achieve amine 19 (Scheme 12).  
The mesylated compound 10 was stirred with sodium azide in dry DMF for 24 h at ambient 
temperature giving compound 17 in excellent yield of 96%. In addition to the elemental 
analysis that showed the absence of sulfur with the simultaneous presence of nitrogen and 
IR spectra, showing the typical peak of azido groups on ν = 2092 cm-1 (Figure 7), the cyclisa-
tion 18 was applied for the confirmation of the structure 17. Glycoside 18 was obtained in 
83% yield by 1,3-cycloaddition of azido compound 17 with phenylacetylene [55]. Finally, 
catalytic hydrogenation of 17 with Pd/C under hydrogen atmosphere led to the primary 
amine 19. In 1H NMR the peak of the protons of the C-1 of the side chain in close vicinity 
to the amine was shifted to 2.71 ppm, previously showed 3.24–3.37 ppm by azido compound 
17. Moreover, no peak of the azido group in IR spectra of the 19 was detected (Figure 7). 
Together with elemental analysis and mass spectrometry, the proposed structure of the 19 
was supported.  
 
i: TBAF, dry acetone, 1.5 h, rt; ii: Phenylacetylene, CuSO4, L(+)-ascorbic acid, wa-
ter/DMF, 63 h, 75 °C; iii: Pd/C, dry methanol, 24 h, rt, H2. 
18 
10 
i 
. 
ii 
. 
iii 
. 
19 
Scheme 12. Synthesis of the primary amine 19. 
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To confirm the structure of 19 chemically, it was treated with benzaldehyde and pyridine-2-
carbaldehyde in dry methanol leading to imines (-CH=N-) 20 and 21 (Scheme 13).  
The rate of the reaction is dependent on the purity of the reagents. So it is highly recom-
mended, to use a fresh batch or at least freshly distilled benzaldehyde and pyridine-2-carbal-
dehyde. The purity of the starting materials is also significant for the purity of the imine. The 
purification and work up could lead to byproducts or even destruction of the Schiff base. In 
1H and 13C NMR spectra peaks indicating aromatic groups were found. In addition, the typ-
ical peaks for -CH=N- were localized at 8.28 ppm for compound 20 and at 8.37 ppm for 
compound 21. In the literature, complexes of ruthenium with iminopyridine ligands were 
N3 
compound 19 
compound 17 
Figure 7. IR spectra of compound 17. 
i: Benzaldehyde, molecular sieve powder, dry methanol, 40 h, rt; ii: Pyridine-2-carbaldehyde, 
molecular sieve powder, dry methanol, 40 h, rt. 
. 
21 20 
i 
. 
ii 
. 
19 
Scheme 13. Synthesis of the Schiff bases. 
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found to have a remarkable activity for the anti-Markovnikov reductive hydrogenation of 
alkynes.[56] Cucciolito et al. have also mentioned glucose containing platinum(II)-Schiff 
base complexes with anticancer activity, showing better water-solubility and minor toxicity 
side effects with respect to other widely used platinum drugs.[57] Furthermore, all the Schiff 
base transition metal complexes derived from cephalexin containing sugars (D-Glucose and 
D-Xylose) and metals such as Fe(II), Co(II), Ni(II) showed more antibacterial activities as 
compared to the pure cephalexin. [58] Such sugar-containing antibiotic complexes could be 
the new step to solve the problem of drug resistance. The increased activity of the drugs, 
especially antibiotics, after its coordination on metal was already studied by Chohan et al. 
[59] 
2.2.4 Synthesis of the 2-deoxy-D-ribofuranose derivatives with pivaloyl groups 
Further, we want to investigate, if other protecting groups besides silyl group on the 3ˈ- and 
5ˈ-positions of the furane ring are possible and if it could lead us to crystalline compounds. 
Until now, all derivatives were syrupy or amorphous, so no X-ray analysis could be per-
formed. We have found that the cleavage of the silyl group of mesylated compound 10 with 
TBAF has resulted in cleavage of mesyl and silyl groups simultaneously, so no subsequent 
reaction to introduce the ethylenediamine was possible (Scheme 14).  
Hence, we went a step in return and transformed the primary alcohol 9 into an acetate 22, 
which was stable to TBAF under the applied conditions (Scheme 15). This reaction was car-
ried out according to the classical procedure for acetylation, mentioned previously in chapter 
2.1.1. The cleavage of the silyl group was performed with TBAF, similarly as prior. Thus, 
compound 23 was achieved in an excellent yield of 96%. For the insertion of pivaloyl groups 
on the 3ˈ- and 5ˈ-positions of compound 23, it was treated with pivaloyl chloride [60] in dry 
DMF. The addition of the 4-(dimethylamino)pyridine (DMAP) as catalyst made the reaction 
5 x faster at room temperature and increased the yield from 20% to 95%. The peaks of the 
pivaloyl groups on the 3ˈ- and 5ˈ-positions of the furane ring were found in 1H NMR at 
1.20 ppm and 1.21 ppm, not overlapping with protons of acetyl group at 2.04 ppm. After the 
introduction of pivaloyl groups the acetyl group was converted into a primary alcohol 25, 
thereafter into mesylate 26 and transfer into ethylenediamine 27. The cleavage of acetyl  
i: TBAF, dry acetone, 1.5 h, rt. 
. 
10 
i 
. 
Scheme 14. The reaction of mesylated compound 15 with TBAF. 
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group in presence of pivaloyl group is sophisticated because of it’s similar reactivity. The 
ancient, well-known and often used procedure of G. Zemplén for the cleavage of acetyl 
group on carbohydrates with NaOMe [61][62] was tested at first. The various concentrations 
from 0.025 M to 1 M and various temperatures from 0 °C to ambient temperature and reac-
tion times from 10 min to 1 h resulted in simultaneous cleavage of the acetyl and one or both 
of the pivaloyl groups. However, the selective deprotection of acetyl in presence of pivaloyl 
was successfully obtained with 0.28 M methanolic HCl solution in dry methanol. To avoid 
the possible migration of pivaloyl groups on the primary alcohol, the deacetylated compound 
25 was used for subsequent reaction without further purification. Following mesylation 26 
and transition into ethylenediamine 27 was carried out according to the procedures men-
tioned before (Scheme 15).  
i: Ac2O, dry pyridine, 15 h, rt; ii: TBAF, dry acetone, 1.5 h, rt; iii: Pivaloyl chloride, DMAP, 
dry DMF, 4 h, rt; iv: Acetyl chloride, dry methanol, 4 h, rt; v: MsCl, NEt3, dry CH2Cl2, 20 min, 
0 °C; vi: ethane-1,2-diamine, dry methanol, 20 h, rt.  
i 
. 
ii 
. 
9 
26 
23 
24 
25 
22 
27 
iii 
. 
iv 
. 
v 
. 
vi 
. 
Scheme 15. The synthesis of ethylenediamine derivative with pivaloyl groups. 
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2.2.5 Synthesis of 2-deoxy-D-ribofuranose derivates with an ethylenediamine group 
via bromination of the allyl group 
We have also investigated another synthetic route for ethylenediamine derivatives starting 
from the 2-deoxy-D-ribofuranose 7. Bromination led to dibromide 28. A subsequent nucle-
ophilic substitution gave diazido compound 29, which was hydrogenated to diamine 31. 
First, a classical bromination with elemental bromine was tested. Due to the high reactivity 
of the bromine, not only addition to the double bond but also partial destruction of the mol-
ecule was observed. Therefore, milder conditions were used, which only allow the selective 
addition of bromine to the double bond of the allyl group. In the variant of Inaba et al. the 
pyridinium tribromide as a mild brominating reagent with subsequent conversion into the 
diazido compound with sodium azide in dry DMF were used.[63] The brominated compound 
28 was used in the next reaction step without further purification since it has started to de-
compose. The dibromination caused an asymmetric center on C-2 of the side chain. The 
following reactions were carried out using the diastereomeric mixture. To obtain the diazido 
compound 29, the brominated compound 28 was treated with sodium azide in dry DMF. The 
reaction was carried out at 70 °C for 2.5 h to give 29 as a colorless syrup. The identity of 
diazido compound 29 was confirmed by analytical data. The IR spectra showed the typical 
azido peaks on the ν = 2100 cm-1 (Figure 9). Cycloaddition of phenylacetylene to diazide 29 
leading to bistriazole 30 was carried out in order to chemically confirm the structure of com-
i: C2H5NHBr3, dry CH2Cl2, 40 min, rt; ii: NaN3, dry DMF, 2.5 h, 70 °C; iii: Pd/C, dry metha-
nol, H2, 24 h, rt; iv: Phenylacetylene, CuSO4, L(+)-ascorbic acid,  
water/DMF, 60 h, 75 °C. 
29 28 
i 
. 
ii 
. 
7 
iii 
. 
iv 
. 
30 31 
Scheme 16. Synthesis of the diamino compound 31. 
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pound 29. The bis(4-phynyl-1H-1,2,3-triazole) 30 was synthesized according to the proce-
dure for the 1,3-cycloaddition of the azide with phenylacetylene, mentioned previously. The 
fair yield of 55% indicates that further improvements of the reaction procedure are desired.  
For the reduction of an azido group to the corresponding amine, various variants are known. 
A principal method is to use a catalyst such as platinum compounds[63] or palladium on car-
bon[64] in the presence of hydrogen. The platinum compounds could also cause the cleavage 
of the silyl protecting group due to the high reactivity, which is undesirable in this case 
because the silyl group is intended to prevent interfering interactions with the hydroxy 
groups during the coordinative bonding with the platinum. Therefore, reduction of the dia-
zido groups to amines with Pd/C was pursued. The reaction was carried out according to the 
classical procedure for the reduction with Pd/C [64] The diamino product 31 was extensively 
analyzed. In addition, elemental analysis confirmed the decrease in the percentage content 
of nitrogen from the azide to the amine.We have also studied the transfer of an azido group 
into an amine via Staudinger reaction. Unexpectedly, the desired diamine product 31 was 
contaminated with dimers of itself. Changes in the reaction conditions did not suppress di-
merisation. We suggest that the formation of dimers could be explained with the 4-mem-
bered-ring transition state,[65], [66] which in our case most probably occurs intermolecularly. 
As a chemical verification for the diamino compound 31 (Scheme 17), it was acetylized to 
give the less polar compound 32. The 1H NMR showed two additional singlets of acetyl 
groups at 1.95 ppm and 1.97 ppm together with the two peaks of NHAc. Regarding the X-
ray analysis, until now, we could not achieve any crystalline products. On that account, the 
cleavage of silyl group was studied to give compound 33, unfortunately, as a colorless syrup. 
N3 
Figure 8. IR spectra of the diazido compound 29. 
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Nevertheless, compound 33 represent a great opportunity for the protection of positions C-
3ˈ and C-5ˈ with subsequent protecting groups. 
The identity of diamino compound 31 was further verified via transformation into diamino 
compound 34. This chemical reaction was carried out with benzaldehyde, molecular sieve 
powder in dry methanol to give diimino compound 34 as a brown-yellow syrup in a very 
good yield. In NMR, ten protons of phenyl and three peaks of NCH (diastereomeric C-2 
protons of the side chain are splitted) were found. Furthermore, we investigated the building 
of cyclic species. Amines are known to react readily as nucleophiles with halide compounds 
and carboxylic derivatives as well as undergo condensation reactions with aldehydes and 
ketones, giving imines. Considering the stability of the ring and the velocity of reaction, 5- 
to 8-membered rings were the optimum. Therefore, species, which contained one to four 
i: Benzaldehyde, molecular sieve powder, dry methanol, 36 h, rt; ii: Ac2O, dry pyridine, 15 h, rt; iii: 
TBAF, dry acetone, 1.5 h, rt; iv: Acetylacetone, dry ethanol, 24 h, rt; 
v: Phthaloyl chloride, dry pyridine, 5 d, rt. 
35 
31 
i 
. 
ii 
. 
iii 
. 
iv 
. 
v 
. 
32 33 
34 
36 
Scheme 17. The subsequent reactions of the diamine compound 31. 
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carbon atoms, were possible for our purpose. As a one-carbon compound, formic acid was 
appropriate. Unfortunately, the treatment of diamine compound 31 with formic acid in tri-
ethyl orthoformate for 4 h at 100 °C [67] led to the formation of side products, so that desired 
compound could not be purified for further analysis. As two-carbon chain compounds, ox-
aldehyde [68], oxalyl chloride and oxalic acid were tested but all with unsatisfactory results. 
The chain with three carbon atoms provided the first positive result. Therefore compound 31 
was treated with acetylacetone in dry ethanol and the reaction mixture was stirred for 24 h 
at ambient temperature to give compound 35 as a brown syrup. In 1H NMR both methyl 
groups and CH2 of the acetylacetone chain was found. The 
1H, 13C NMR correlation spectra 
(HMBC) showed the correlation between C-1 of the side chain and CH2 of the acetylacetone. 
Interestingly, the correlation between diastereomeric C-2 of the side chain and CH2 of the 
acetylacetone in HMBC was not observed, most probably, the weak signal of one diastere-
omeric proton was not detectable above the base line noise. Moreover, we assume that the 
probable dynamic effects of the new cyclic diimine structure could also have an effect on 
the correlation intensity in NMR. Ensuing, we want to verify if this effect takes place on the 
other cyclic species. Considering that, the reaction of diamine 31 with diethyl malonate, the 
other 3 carbon atoms species, was tested. Perfectly, the reaction of diamine with diethyl 
malonate in dry ethanol is supposed to be byproduct-free, because the ethanol is the only 
byproduct of the reaction and acts simultaneously as a solvent. But the lactam-lactim tau-
tomerie of the isolated product was very vigorous, causing very wide signals in the 1H NMR, 
which could not be analyzed or allocated. Finally, we have tested the cyclization of diamine 
31 with phthaloyl chloride. This reagent, contributing with 4 carbon atoms to the ring, has 
also a potentially stabilizing phenyl moiety between both lactams. Reagent 31 was treated 
with phthaloyl chloride in dry pyridine to give compound 36 as a brown syrup. As we have 
predicted, the phenyl moiety stabilized the ring, so that characterization of the product was 
successfully achieved. The 1H and 13C NMR exhibited the typical phenyl signals. Support-
ively, 1H, 13C NMR correlation spectra (HMBC) showed the correlation between C-1 of the 
side chain and phenyl. Here, the correlation of C-2 of the side chain and phenyl was also not 
observed, supporting our presumption mentioned previously. Retrospectively, we could say, 
that two amines are included in diamine compound 31 and are available for the further reac-
tions. 
2.2.6 Synthesis of ethylenediamine derivates with pivaloyl protecting groups  
After the verification of the diamino structure, we studied the removal of the silyl group and 
further introduction of other protecting groups on the C-3ˈ and C-5ˈ positions of the pseudo-
sugar ring (Scheme 18). Because of the high polarity of the diamino compound, the cleavage 
of the silyl group occurred according to the standard procedure with TBAF starting with 
diazo compound 29. The reaction mixture was stirred for 2 h to give unprotected diazo com-
pound 37 as a light-yellow syrup in a very good yield. In the 1H NMR no signal from the 
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silyl group was observed, additionally elemental analysis confirmed the calculated amount 
of nitrogen.  
The protection of hydroxyl groups on C-3ˈ and C-5ˈwith the benzoyl group was also studied. 
NMR spectra showed residues of benzoyl chloride together with the desired product. Hence, 
the insertion of pivaloyl groups brought satisfactory results. For the reaction of diol 37 with 
pivaloyl chloride, similar reaction conditions were used. Here, addition of the 4-(dimethyl-
amino)pyridine (DMAP) also led to an increase of the reaction rate giving the desired pro-
tected product 38 after 2.5 h. The subsequent reduction of diazo compound 38 to diamine 39 
was achieved via reduction using palladium on carbon. The diamino compound 39 was con-
firmed analytically. Nevertheless, acetylation leading to diamide 40 was accomplished. Be-
side the protons of the pivaloyl groups in 1H NMR the signals for the acetyl groups were 
found, giving the multiplet together with protons on C-3 and C-2ˈ. Supportively, the 1H, 13C 
NMR correlation spectra (HMBC) showed unambiguously that the positions C-3ˈ and C-5ˈ 
of the pseudo-sugar ring are protected with pivaloyl moieties. Further, the stearoyl chloride, 
derivative of stearic acid (18:0) one of the most common saturated fatty acids found in na-
ture, was also studied as a structural element and further building block of the biomembrane. 
i: TBAF, dry acetone, 2 h, rt; ii: Stearoyl chloride, DMAP, dry pyridine, 2 h, rt; iii: Pivaloyl 
chloride, DMAP, dry pyridine, 2.5 h, rt; iv: Pd/C, dry methanol, 24 h, rt, H2; 
 v: Ac2O, dry pyridine, 15 h, rt. 
38 
29 
i 
. 
37 
ii 
. 
iii 
. 
iv 
. 
v 
. 
39 40 
41 
Scheme 18. Synthesis of the compounds with pivaloyl and stearoyl groups. 
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The reaction of 37 with stearoyl chloride and DMAP in dry pyridine achieved the formation 
of diazo compound 41 with two stearoyl groups on C-3ˈ and C-5ˈ. The white amorphous 
solid was exhaustively characterized. Unfortunately, further reduction of the diazo groups 
was not successful. The classical solvent (methanol) for  reduction with Pd/C did not com-
pletely dissolve the starting compound 41. To dissolve the substrat some amount of chloro-
form was needed, causing difficulties to remove Pd/C by filtration. 
2.2.7 Synthesis of 2-deoxy-D-ribofuranose derivates with phosphoramidite 
In this chapter, the synthesis of a phosphoramidite derivative is presented. Starting with 
deprotected derivative 37, suitable building blocks for use in automated oligonucleotide syn-
thesis were achieved (Scheme 19).  
To achieve the building blocks for the use in automated oligonucleotide synthesis, the 5ˈ-
hydroxyl group should be temporary protected to avoid undesired by-products. The follow-
ing introduction of the phosphoramidite group to the 3ˈ-position gives the desired building 
blocks for the solid phase synthesis. The 4,4ˈ-dimethoxytrityl group (DMTr or DMT) was 
established as a standard for the protection of 5ˈ-position. Advantageously, DMTr is remov-
able under mild acidic conditions and the measurement of absorption in the range of 498 nm 
according to the DMTr cation gave indirect response about the yield of the solid phase syn-
thesis. [69], [70] The reaction with 4,4ˈ-dimethoxytrityl is well known. Therefore, alcohol 37 
was treated with 4,4ˈ-dimethoxytrityl chloride, DMAP and triethylamine in dry DMF.[71] 
The reaction mixture was stirred for 24 h at ambient temperature to give 42 as a yellow syrup 
i: DMTrCl, DMAP, dry DMF, 24 h, rt; ii: 2-cyanoethyl N,N-diisopropylchlorophosphoramidite, 
diisopropylethylamine, dry CH2Cl2, 3 h, rt. 
i 
. 
37 
ii 
. 
43 
42 
Scheme 19. Synthesis of the phosphoramidite derivative. 
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in a good yield. In 1H and 13C NMR spectra, the typical signals of the 4,4ˈ-dimethoxytrityl 
group together with the hydroxyl group on C-3ˈ position were observed. Additionally, the 
1H, 13C NMR correlation spectra (HMBC) showed the correlation between the 5ˈ-position 
and the 4,4ˈ-dimethoxytrityl group. Together with further spectra, everything points to the 
given structure 42. Reporting the activity of modified dinucleotides against an enzyme pro-
duced by a retrovirus (such as HIV), Y. Aubert et al. published the classical procedure for 
the introduction of phosphoramidites.[72] We used Aubert’s approach to synthesize phospho-
ramidite derivative 43. Compound 42 was dried by co-evaporation with dry pyridine and left 
under vacuum overnight. Using commercially available phosphitilating reagent 2-cyano-
ethyl N,N-diisopropylchlorophosphoramidite, the reaction was found to occur after stirring 
the mixture of the phosphitilating reagent, compound 42 and diisopropylethylamine in dry 
CH2Cl2. The 1% v/v of the triethylamine was added to the eluent by the flash chromatog-
raphy to protect the 4,4ˈ-dimethoxytrityl group from the cleavage via slight acidic silica gel. 
Product 43 was obtained as a mixture of diastereomers in a yield of 60% as a yellow syrup. 
All analytic data confirm the structure 43. In 1H and 13C NMR spectra the new signals for 
the cyanoethyl and diisopropyl group were observed. Using COSY, HSQC and HMBC ex-
periments all signals could be assigned. The elemental analysis and HRMS were in accord-
ance with expected values. Both isomers could be used without separation in the oligonucle-
otide solid phase synthesis. The stereochemical information at the phosphorus atom is lost 
by the oxidation of the coupled nucleosides to phosphatesters. Hence, tedious separation of 
the diastereomers can be omitted. 
2.3 Research application 
The purpose of this work was to synthesize potential intermediates for antiviral and anti-
tumor reagents. Therefore, we want to test some compounds for it’s further application as 
potential biologic active reagents. 
2.3.1 Reaction of the β-allyl-C-glucoside of the 2-desoxy-D-ribofuranose with 
titanocene 
Exo-glycals are important intermediates in natural product synthesis and could be conjugated 
into the spiro-compound, having one carbon atom as a part of the glucose scaffold and sim-
ultaneously as a part of the heterocycle. For example, the microwave irradiation assisted 1,3-
dipolar cycloaddition of exo-glucals with aryl nitrones was found to be stereoselective for 
the synthesis of the spiro-isoxazolidine glycosides by X. Li et al. Furthermore, the spiro-
isoxazolidine glycosides were found to have an inhibitor activity against α-Amylase, α- and 
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β-Glucosidase, and even antitumor activity against Hela cell lines4.[73] The deprotected spiro-
isoxalines were evaluated as inhibitors of muscle glycogen phosphorylase b (GPb), acting 
as a potential agent in improving glycemic control in type 2 diabetes.[74] Besides the excellent 
biological activity as an enzyme inhibitor, the synthesis of the exo-glucals is sophisticated, 
requiring rough reaction conditions and multiple steps procedure.[75] Nevertheless, the exo-
glucals can be also obtained via a iridium(I) catalysed stereoselective isomerisation reaction 
of the C-allyl glycosides giving (E)-C-vinyl glycosides and (Z)-exo-glycals.[76] Subse-
quently, the olefin isomerisation reactions to the (E)- and (Z)-products via metal catalysts 
like iron [77], cobalt [78], nickel [79], rhodium [80], ruthenium [81], palladium [82], [83] and iridium 
[84] are known. There are also numerous titanocene compounds known as a catalysts for the 
isomerisation of olefins.[85]  
Here, we chose to examine the reaction of β-C-allylglucoside of the 2-desoxy-D-ribofuranose 
7 with titanocene species. This work was done in cooperation with Leibniz Institute for Ca-
talysis by Dr. Melanie Reiß.5 The β-C-allylglucoside 7 was treated with equimolar amount 
of titanocene in dry toluene and the reaction mixture was stirred for 4 d at 60 °C. After aque-
ous work up the tinane species was separated via flash chromatography with 1:1 EtOAc/n-
Hexane eluent. The NMR spectra carried out at a 500 MHz device confirming the structure 
in Scheme 20. Unfortunately, the titanocene was found to isomerize the allyl group selectively 
giving just the (E)-C-vinyl glycosides and no reaction to the (Z)-exo-glycals was observed. 
However, it is still unclear if the titanocene has acted as a promoter or the reaction proceeded 
catalytically. Nevertheless, the (E)-C-vinyl glycosides could be further developed into the 
diamine species with shorter carbon chain or even into heterocycles. In this way, advanced 
potential antiviral and antitumor intermediates of the glycosides could be obtained. 
                                                 
4 The human cervical cancer cells  
5 Leibniz Institute for Catalysis, Albert-Einstein-Str. 29a, 18059 Rostock, Germany 
i: dry toluene, 4 d, 60 °C. 
i 
. 
7 
+ 
. 
Scheme 20. Reaction of the β-C-allylglucoside with titanocene. 
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2.3.2 Reaction of the diamine of the 2-deoxy-D-ribofuranose with K2PtCl4 
Beside the interest in new metal ions for cancer chemotherapy, platinum based drugs, espe-
cially cisplatin (cis-Pt(NH3)2Cl2), are still the most used. The design of cisplatin analogues 
plays the key role to find more potent antitumor drugs with the same efficiency, simultane-
ously, to overcome the disadvantages of clinically used platinum based drugs. Therefore, we 
have tested some of the compounds to investigate their reactivity with platinum. For this 
purpose, the four 2-deoxy-D-ribofuranose diamine compounds, showing in Figure 9, were 
studied.  
 
The preliminary experiments were accomplished by the working group of Prof. Dr. Wolfram 
Seidel.6 It was investigated whether the coupling of the carbohydrate ligand 15 with the met-
als was possible. The ruthenium-sugar complex starting from compound 15 was successfully 
obtained (Figure 10). Moreover, the similar cis-ruthenium complexes but without a mono-
saccharide unit are known from the literature and have been characterized as highly soluble 
in water and effective against various types of tumors.[86] 
                                                 
6    University of Rostock, department of anorganic chemistry, Albert-Einstein-Straße 3a, 18059 Rostock,     
Germany 
39 
15 
27 
31 
Figure 9. The diamine compounds for platinum complexes. 
cis-ruthenium-carbohydrate complex 
with compound 15. 
Figure 10. The ruthenium-sugar complex. 
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Further, we have investigated the synthesis of the complexes with platinum. There are a few 
approachs to synthesize the platinum complexes, to differ in starting platinum compounds 
and the reaction conditions. Gianini et al. have prepared the platinum complexes starting 
with Pt(SEt2)2Cl2 in THF as a solvent for 1.5 h at -70 °C → 0 °C in a “Schlenk” flask under 
argon.[87] Hanessian et al. have reported the coordination of K2PtCl4 in aqueous solution 
setting for 2 h at the ambient temperature.[64] The same reaction conditions were also known 
from Mikata et al. In his work, the eight carbohydrate-pendant platinum(II) complexes, con-
taining the unprotected pyranose derivatives of D-/L-glucose, D-mannose, D-galactose and 
D-xylose were prepared. The sugar containing platinum(II) complexes have promising anti-
cancer activity and reduced the toxicity inherent with platinum(II) complexes.[88] The other 
glucose containing platinum(II)- Schiff base complexes were published by Cucciolito et al. 
These platinum(II) complexes were obtained from PtCl2(DMSO)2 in dioxane for 0.5 h at 
25 °C.[57] In our case, the starting diamine were well soluble in methanol, so the method of 
Palmer et al. was found to be the best course of action. Here, the synthesis of platinum(II) 
complexes was proceeded with K2PtCl4 and NaHCO3 in methanol/water at ambient temper-
ature for 2.5 h. The further stirring of the reaction mixture with 5% aqueous KCl has asso-
ciated the precipitation of the desired complexes.[89] We used slightly a varied Palmer’s ap-
proach to prepare the platinum(II) complexes.  
For the synthesis of the platinum(II) complexes, the four 2-deoxy-D-ribofuranose diamine 
compounds 15, 27, 31 and 39 were dissolved in water/methanol 1.5:1 and treated with 
equimolar amounts of K2PtCl4 and 1.5 eq NaHCO3 dissolved in a small amount of water. 
After stirring for 3 h at room temperature in the dark, aq 5% KCl solution was added and the 
reaction mixture was stirred for further 2.5 h at ambient temperature. After that, the yellow 
precipitant was filtered and washed twice with water. The product was obtained as a yellow 
powder. A variety of crystallisation procedures were examined. Unfortunately, no crystals 
could be isolated.  
The NMR showed a slight shift of protons close to platinum. The 195Pt NMR showed no 
sharp signal for platinum, but a very broad signal was found in the expected shift region. 
However, electrospray ionization ion trap mass spectrometry (ESI-ITMS) unveiled an unex-
pected result. 
We have found, that the usage of NaHCO3 led to the desired platinum(II) complexes, but in 
the form of dimers (Scheme 21). The reaction without NaHCO3 produced only the monomeric 
complex. Interestingly, this phenomenon was applicable only while using sugar as a ligand. 
Experiments with phenylenediamine produced monomeric complexes in both cases, with 
base and without base, under the same reaction conditions. Due to the amorphous nature of 
the complex, X-ray analysis was not possible. Hence, the exact structure of the dimer could 
not be determined. 
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i:1) K2PtCl4, 3 h, rt, 2) aq 5% KCl, 2.5 h, rt; ii: 1) K2PtCl4, NaHCO3, 3 h, rt,  
2) aq 5% KCl, 2.5 h, rt. 
 
29 
i 
. 
ii 
. 
no base 
. 
with base 
. 
Scheme 21. Synthesis and proposed structure of the platinum(II) glucoside complexes. 
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3 Summary 
The aim of this work was to achieve potential intermediates for antiviral and antitumor 
agents. Hence, we focused on the development of the 2-deoxy-D-ribofuranose analogues 
with diamine moieties that should be able to form metal complexes similar to cisplatin. 
In the first part, a β-allyl-C-glycoside was prepared. Starting with the D-ribofuranose via 2-
deoxy-D-ribofuranose using the allyl group on the furan ring as a spacer unit for attachment 
of the ethylenediamine group. First, the D-ribose was fixed by an isopropylidene protecting 
group on carbon atoms C-2' and C-3' in their furanose form in a yield of 87% (1a), whereby 
the formation of the protected pyranose as byproduct was resulted (1b). Next, the acetylation 
of the free hydroxyl groups was performed in a yield of 95% (2). The subsequent introduc-
tion of the allyl group having a double bond at the terminal end was targeted at the anomeric 
center of the furan ring (3). Due to the steric hindrance of the α-side by a methyl group of 
the isopropylidene protecting group, the introduction of the allyl group in the desired β-
position was achieved in a yield of 78%. We have succeeded in carrying out the removal of 
all protecting groups to form compound 4 in a yield of 85%. The optimized reaction condi-
tions of the silylation resulted in a fixation of the 3'- and 5'-positions of the furane ring (5). 
The remaining free hydroxyl group of compound 5 was reductively removed after exchange 
with iodine (6). Thus, the 2-deoxy-D-ribofuranose derivative 7 was obtained in a yield of 
89%. The cleavage of the silyl group led to the unprotected β-allyl-C-glycoside of the 2-
deoxy-D-ribofuranose (8). The complete reaction pathway of compounds 1-8 was verified 
and the total yield was markedly improved by 54% (Scheme 22). 
Then, starting from compound 7, two different methods were developed to get differently 
long spacer chains of the C-glycoside. The first variant involved oxidative hydroboration 9, 
subsequent mesylation rendered 10 as a substrate for the formation of ethylenediamine 15.  
8 3 
3 steps 
5 steps 
Scheme 22. Synthesis of the unprotected 2-deoxy-D-ribofuranose derivative 8 via important inter-
mediate 3. 
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Moreover, the further reaction of the mesylated compound 10 with subsequent nucleophiles 
gained products 11-14. Mesylate 10 was further converted into azide 17, which was verified 
by transformation into triazole 18. A following reduction of azide 17 gave the primary amine 
19. The subsequent reaction of primary amine 19 to imines 20 and 21 confirmed its proposed 
structure. Diamine 15 was tested, for the introduction of further protecting groups on the C-
3' and C-5' positions of the furane ring. Due to the lability of the mesyl group upon treatment 
with TBAF, another synthetic pathway was developed. Here, the primary alcohol 9 was con-
verted into acetate 22, which was successfully deprotected, giving diol 23. Following allo-
cation of the 3'- and 5'-positions of the furane ring gave pivalate 24. Acidic transesterification 
gave alcohol 25, which upon mesylation gave compound 26. Nucleophilic substitution of 
the mesylate gave diamino compound 27 in a yield of 80%. 
The second pathway starting from compound 7 involves bromination of the allyl double 
bond, giving dibromide 28. Nucleophilic substitution with NaN3 led to diazide 29. A subse-
quent reduction gave diamine 31. Through this route, the other target substance bearing a 
diamine moiety 31 was obtained in a yield of 93%. The diamine structure (31) was confirmed 
via acetylation to the corresponding amide 32, conversion into diimine 34, as well as cy-
clisation of the diamine giving 35 and 36. Starting with diazido compound 29, the silyl group 
was cleaved via TBAF, gave diol 37. Introduction of pivaloyl groups on the 3'- and 5'-posi-
tions (38) and a following reduction gave diamine 39 in a yield of 90%. The unprotected 
diazido compound 37 was found to be optimal for the introduction of further protecting 
groups, like stearoyl (product 41) or even the DMTr (product 42) together with phospho-
ramidite derivative 43, achieving the potential building blocks for the automated oligonucle-
otide synthesis. 
Thus, we have succeeded in obtaining several 2-deoxy-D-ribofuranose derivatives with an 
ethylenediamine group on a spacer with one or three carbon atoms to the sugar moiety (Figure 
11).  
39 
15 
27 
31 
Figure 11. Several 2-deoxy-d-ribofuranose derivatives with an ethylenediamine group. 
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Subsequently, in cooperation with the working group of Prof. W. Seidel, it was investigated 
whether coordination of sugar ligand 15 to a metal, was possible. And indeed, a ruthenium-
sugar complex was successfully prepared (Figure 10).  
Considering the cooperation with Dr. Melanie Reiß from the Leibniz Institute for Catalysis, 
we could mention, that the use of carbohydrate-based species, as well as carbohydrate-based 
diamine complexes does not only have to be limited to medical aspects. It provides a previ-
ously unexplored field of investigation in catalysis (for example as a catalysts for direct aldol 
reactions [90] or as catalyst for non-enzymatic hydrolysis of RNA [91]), for the synthesis of 
molecular recognition structures,[92] and as a functional group in the synthesis of macrocy-
cles [92], [93] and polymers [94]. 
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4 Experimental Section 
4.1 General 
4.1.1 Reagents and materials 
All solvents and reagents were purified and dried according to standard procedures [95]. 
Washing solutions used here, like saturated aqueous NaHCO3 solution, saturated aqueous 
NaCl solution, saturated aqueous Na2S2O3 solution and 15% aqueous NaHSO4 solution, were 
cooled to  ̴4 °C. 
Thin-layer chromatography (TLC) to monitor the reactions were performed using silica gel 
on aluminum foil (silica gel 60, F254, layer thickness 0.2 mm, MERCK). The detection of 
products with amino groups was pursued by UV-absorption on 254 nm and by charring with 
ethanolic 10% H2SO4 solution. For other compounds the detection was pursued by UV-
absorption on 254 nm and by charring with a mixture of ethanol, concentrated H2SO4 and 3-
methoxyphenol (1000:10:1 v/v). The colors may range from deep violet to light pink or 
brown, even greenish, blueish or greyish spots were observed. 
Flash chromatography was performed on slurry-packed silica gel 60 (63-200 µm, MERCK). 
The solvent systems are described in the experimental section for each compound separately. 
The mixing ratios of the solvent systems are volume ratios. The eluents were distilled before 
their use. Petroleum ether was used as a 60 °C – 80 °C fraction. 
Solutions in organic solvents were dried over MgSO4 and concentrated under reduced pres-
sure (rotary evaporator). 
4.1.2 Analytics 
Melting points were determined with a Boetius micro-heating plate BHMK 05 (Rapido, 
Dresden) and were not corrected. Optical rotation was measured with a digital polarimeter 
GYROMAT (Dr. Kernchen GmbH) for solutions in dry CHCl3, dry CH2Cl2 and dry metha-
nol using a 2 cm cuvette. 
1H NMR spectra (250.13, 300.13 and 500.13 MHz) and 13C NMR spectra (62.89, 75.47 and 
125.76 MHz) were recorded on BRUKER AC 250, ARX 300 and AVANCE 500. The cali-
bration of spectra was carried out on solvent signals (CDCl3: δ 1H = 7.27 ppm, δ 13C = 
77.00 ppm; MeOH-d4: δ 1H = 3.31 ppm, δ 13C = 49.15 ppm). The following abbreviations 
were applied characterizing the signal splitting: s = singlet, d = doublet, dd = doublet of 
doublets, ddd = doublet of doublet of doublet, t = triplet, q= quartet, quint = quintet, sext = 
sextet, sept = septet, m = multiplet. The 1H and 13C NMR signals were assigned by distor-
tionless enhancement by polarization transfer (DEPT), two-dimensional 1H, 1H homonuclear 
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correlation spectroscopy (COSY), nuclear overhauser enhancement and exchange spectros-
copy (NOESY), 1H, 13C correlation spectra (HMBC) and heteronuclear single quantum co-
herence (HSQC). 
Elemental analysis was recorded on a CHNS Flash EA 1112 (Thermoquest). The mass spec-
tra were performed on an AMD 402/3 spectrometer (AMD Intectra GmbH) and the HR-MS 
(ESI) analysis, on a LTQ Thermo Finnigan spectrometer. 
4.2 Synthesis of the multistep compounds 
4.2.1 Introduction of the isopropylidene protecting group 
Concentrated sulphuric acid (0.34 ml) was added dropwise to a vigorously stirred suspension 
of D-ribose (15.0 g, 100 mmol) in dry acetone (150 ml). After stirring for 2 h at ambient 
temperature (monitored by TLC in petroleum ether – EtOAc 1:2 with 1% NEt3), the clear 
light-yellow solution was cautiously neutralized (ice bath) by addition of solid calcium hy-
droxide. After filtration using a glass sintered-filter funnel equipped with a layer of silica 
gel, the solids were washed with acetone (3 × 30 ml) and the combined filtrates were con-
centrated. Chromatography (petroleum ether – EtOAc 1:2 with 1% NEt3) gave first 1,2:3,4-
di-O-isopropylidene-α-D-ribopyranose (1b). Eluated next was the desired compound 2,3-O-
Isopropylidene-β-D-ribofuranose (1a).  
4.2.1.1  ((3aR,4R,6S,6aR)-6-acetoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-
yl)methyl acetate (1a) 
 
Yield:  16.5 g (87%), light-yellow syrup 
[α]
D
24 :  –24.5 (c 1.0, CHCl3)  
Rf:  0.37 (PE:EtOAc 1:2 with 1% NEt3) 
1H NMR (300.13 MHz, CDCl3): δ 1.33, 1.49 [2 x s, 6H, 2 x C(CH3)2], 3.62–3.79 (m, 3H, 
H-5', OH), 4.40–4.42 (m, 1H, H-4'), 4.58 (d, 1H, 3J2',3' = 6.0 Hz, H-2'), 4.83 (dd, 1H,
 3J2',3' = 
5.9 Hz, 3J3',4' = 1.0 Hz, H-3'), 5.03 (br s, 1H, OH), 5.41 (s, 1H, H-1'). 
1' 
5' 
4' 
2' 3' 
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13C NMR (75.47 MHz, CDCl3): δ 24.74, 26.38 [2 x C(CH3)2], 63.62 (C-5'), 81.63(C-3'), 
86.77 (C-2'), 87.72 (C-4'), 102.91 (C-1'), 112.10 [C(CH3)2]. 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C8H14O5 [M+Na]
+
: 213.07334, found 
213.07329. 
C8H14O5 (190.19) calcd:   C 50.52 H 7.42 
 found:  C 50.31 H 7.41 
   
4.2.1.2 (3aR,5aR,8aR)-2,2,7,7-tetramethyltetrahydro-5H-bis([1,3]dioxolo)[4,5-b:4',5'-
d]pyran (1b) 
 
Yield:  99.7 mg (0.4%), colorless crystals 
[α]
D
24
:  –39.4 (c 1.0, CHCl3) 
mp:  63–64 °C 
Rf:  0.32 (PE:EtOAc 2:1 with 1% NEt3) 
1H NMR (300.13 MHz, CDCl3): δ 1.35, 1.38, 1.55, 1.60 [4 x s, 12H, 2 x C(CH3)2], 3.81– 
3.89, 4.01 (m, 2H, H-5'), 4.25 (m, 1H, H-3'), 4.41–4.52 (m, 2H, H-2', H-4'), 5.44 (d, 1H, 3J1,2 
= 2.5 Hz, H-1'). 
13C NMR (62.90 MHz, CDCl3): δ 25.02, 25.28, 26.09, 26.36 [2 x C(CH3)2], 61.24 (C-5'), 
69.60, 72.04, 72.06 (C-2', C-3', C-4'), 96.49 (C-1'), 109.45, 110.84 [2 x C(CH3)2]. 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C11H18O5 [M+Na]
+: 253.10464, found 
253.10463 
C11H18O5 (230.26) calcd:  C 57.38 H 7.88 
 found: C 57.36 H 7.97 
1' 
2' 
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4.2.2 ((3aR,4R,6S,6aR)-6-acetoxy-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-
yl)methyl acetate (2)  
Freshly distilled Ac2O (15 ml) was added (dropwise at 0 °C) to a vigorously stirred solution 
of 1a (5.0 g, 26 mmol) in dry pyridine (30 ml). The mixture was allowed to attain ambient 
temperature and stirring was continued overnight. TLC (petroleum ether – EtOAc 2:1 with 
1% NEt3) showed then that the reaction was complete. Excess of Ac2O was then destroyed 
by addition of methanol (10 ml) at 0 °C and stirring was continued for additional 30 min. 
The mixture was poured into iced water and the aqueous phase was extracted with CH2Cl2 
(3 × 50 ml). The combined organic phases were successively washed with aq 15% NaHSO4 
(3 × 50 ml), ice water (70 ml), and sat aq NaHCO3 solution (2 × 50 ml), then dried and 
concentrated. Chromatography (petroleum ether – EtOAc 2:1 with 1% NEt3) gave the com-
pound 2. 
Yield:  6.7 g (93%), colorless syrup 
[α]
D
23
:  –61.0 (c 1.0, CHCl3) 
Rf:  0.30 (PE:EtOAc 2:1 with 1% NEt3) 
1H NMR (300.13 MHz, CDCl3): δ 1.34, 1.50 [2 x s, 6H, C(CH3)2], 2.06, 2.09 (2 x s, 6H, 2 
x COCH3), 4.12 (d, 1H, 
2J5'a,5b = 2.6 Hz, H-5'a), 4.14 (d, 1H, 
2J5'a,5'b = 2.6 Hz, H-5'b), 4.47 
(dd, 1H, 3J4',5a' = 7.1 Hz, 
3J4',5b' = 6.5 Hz, H-4'), 4.72 (s, 2H, H-2', H-3'), 6.22 (s, 1H, H-1'). 
13C NMR (62.90 MHz, CDCl3): δ 20.76, 21.13 (2 x COCH3), 25.04, 26.41 [2 x C(CH3)2], 
64.04 (C-5'), 81.54 (C-3'), 85.09 (C-2'), 85.33 (C-4'), 102.12 (C-1'), 113.22 (C(CH3)2), 
169.24, 170.45 (2 x COCH3). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C12H18O7 [M+Na]
+: 297.09447, found 
297.09478. 
C12H18O7 (274.27) calcd:   C 52.55 H 6.62 
 found:  C 52.41 H 6.45 
2' 
1' 
3' 
4' 
5' 
  40 
4.2.3  ((3aR,4R,6S,6aS)-6-allyl-2,2-dimethyltetrahydrofuro[3,4-d][1,3]dioxol-4-
yl)methyl acetate (3) 
ZnBr2 (6.5 g, 29 mmol; fresh batch, avoid any contact with air and moisture!) was added to 
a stirred solution of 2 (3.0 g, 11 mmol) in dry freshly distilled MeNO2 (50 ml; 4 h boiled 
over CaH2 for drying) at 0 °C under argon atmosphere. Allyltrimethylsilane (8.3 ml, 52 
mmol) was added during 30 min at 0 °C, and stirring was continued for additional 90 min at 
ambient temperature under argon atmosphere (monitored by TLC in petroleum ether – 
EtOAc 6:1 with 1% NEt3). Sat aq NaHCO3 (150 ml) was added, and the mixture was ex-
tracted with CH2Cl2 (3 × 100 ml). To prevent an emulsion layer, both the ratio between the 
organic phase and water should be adhered, and vigorously shaking of the mixture must be 
avoided. The combined organic phases were dried and concentrated. Chromatography (pe-
troleum ether – EtOAc 6:1 with 1% NEt3) provided compound 3. 
Yield:  2.2 g (78%), colorless syrup 
[α]
D
22
:  +12.2 (c 1.0, CHCl3) 
Rf:  0.3 (PE:EtOAc 6:1 with 1% NEt3) 
1H NMR (300.13 MHz, CDCl3): δ 1.34, 1.50 [2 x s, 6H, C(CH3)2], 2.10 (s, 3H, COCH3), 
2.35–2.41 (m, 2H, H-3), 3.97–4.03 (m, 1H, H-1'), 4.08–4.14 (m, 2H, H-5'a, H-4'), 4.24–4.31 
(m, 1H, H-5'b), 4.39 (dd, 1H, 3J2',3' = 6.9 Hz, 
3J1',2' = 4.4 Hz, H-2'), 4.49 (dd, 1H,
 3J2',3' = 6.9 
Hz, 3J3',4' = 4.4 Hz, H-3'), 5.10–5.20 (m, 2H, H-1), 5.75– 5.91 (m, 1H, H-2). 
13C NMR (75.47 MHz, CDCl3): δ 20.82 (COCH3), 25.50, 27.37 [2 x C(CH3)2], 37.74 (C-
3), 64.36 (C-5'), 81.62 (C-4'), 81.90 (C-3'), 83.73 (C-1'), 83.89 (C-2'), 114.67 [C(CH3)2], 
117.94 (C-1), 133.24 (C-2), 170.68 (COCH3). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C13H20O5 [M+H]
+: 257.13835, found 
257.13851.  
C13H20O5 (256.29) calcd:   C 60.92 H 7.87 
 found:   C 60.72 H 7.65 
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4.2.4  (2S,3R,4S,5R)-2-allyl-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (4)  
1.0 M aq HCl (19.3 ml) was added to a solution of 3 (8.0 g, 31 mmol) in ethanol (15 ml), 
and the mixture was stirred for 2 d at ambient temperature (monitored by TLC in petroleum 
ether – EtOAc 11:1). The mixture was neutralized with solid NaHCO3, filtered, a small 
amount of silica gel (ca. 8 g, suitable for flash chromatography) was added, and the mixture 
was concentrated. Chromatography (EtOAc–MeOH 11:1) gave compound 4. 
Yield:  4.6 g (85%), amorphous solid 
mp:  41–43 °C 
Rf:  0.36 (EtOAc:MeOH 11:1) 
[α]
D
22
:  –4.6 (c 1.0, MeOH) 
1H NMR (300.13 MHz, CDCl3): δ 2.28–2.52 (m, 2H, H-3), 2.52–2.67 (m, 1H, OH-5'), 
3.10–3.22 (m, 1H, OH-2'), 3.32–3.56 (m, 1H, OH-3'), 3.61–3.75 (m, 1H, H-5'a), 3.77– 3.91 
(m, 4H, H-1', H-2', H-4', H-5'b), 4.00–4.06 (m, 1H, H-3'), 5.09–5.21 (m, 2H, H-1), 5.77–
5.92 (m, 1H, H-2). 
13C NMR (62.90 MHz, CDCl3): δ 37.57 (C-3), 62.53 (C-5'), 71.38 (C-3'), 74.25 (C-2'), 
82.72 (C-1'), 83.34 (C-4'), 117.98 (C-1), 133.66 (C-2). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C8H14O4 [M+Na]
+: 197.07843, found 
197.07869. 
C8H14O4 (174.19) ber.: C 55.16 H 8.10 
 gef.: C 55.08 H 7.98 
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4.2.5 (6aR,8S,9S,9aS)-8-allyl-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5, 
2,4]trioxadisilocin-9-ol (5)  
1,3-dichloro-1,1,3,3-tetraisopropyldisiloxane (2.4 ml, 7.4 mmol) and imidazole (2.1 g, 31 
mmol) were added at 0 °C to a solution of 4 (1.2 g, 7 mmol) in dry DMF (17 ml). After 
stirring at 0 °C for 1 h (monitored by TLC in petroleum ether – EtOAc 5:1), the mixture was 
poured into iced water (150 ml). The aqueous phase was extracted with CH2Cl2 (4 × 70 ml), 
and the combined organic phases were washed with sat aq NaHCO3 (60 ml), dried, and con-
centrated. Chromatography (petroleum ether – EtOAc 11:1) afforded compound 5. 
Yield:  2.5 g (85%), colorless syrup 
Rf:  0.39 (PE:EtOAc 11:1) 
[α]
D
22
:  –16.0 (c 1.0, CHCl3) 
1H NMR (300.13 MHz, CDCl3): δ 0.96–1.14 [m, 28H, 4 x CH(CH3)2], 2.28–2.44 (m, 2H, 
H-3), 2.83 (d, 1H, 3JOH,H-2' = 3.7 Hz, OH-2'), 3.77–3.92 (m, 4H, H-1', H-2', H-4', H-5'a), 4.02 
(dd, 1H,
 2J5'a,5'b = 12.0 Hz, 
3J4',5'b = 3.2 Hz, H-5'b), 4.20 (t, 1H, 
3J2',3' = 
3J3',4' = 6.5 Hz, H-3'), 
5.07–5.18 (m, 2H, H-1), 5.81–5.94 (m, 1H, H-2). 
13C NMR (75.47 MHz, CDCl3): δ 12.64, 12.78, 13.18, 13.36 [4 x CH(CH3)2], 16.93, 17.00, 
17.03, 17.15, 17.28, 17.31 (2), 17.42 [4 x CH(CH3)2], 37.74 (C-3), 62.70 (C-5'), 72.22 (C-
2'), 73.81 (C-3'), 82.17 (C-4'), 83.36 (C-1'), 117.46 (C-1), 133.87 (C-2). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C20H40O5Si2 [M+H]
+
: 417.24870, found 
417.24938. 
C20H40O5Si2 (416.70) calcd:   C 57.65 H 9.68 
 found:  C 57.51 H 9.73 
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4.2.6  (6aR,8S,9R,9aR)-8-allyl-9-iodo-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-
f][1,3,5,2,4]trioxadisilocin (6)  
A mixture of 5 (2.0 g, 5 mmol), triphenylphosphane (3.3 g, 12.6 mmol), imidazole (885 mg, 
13 mmol), and iodine (1.9 g, 7.5 mmol) in dry toluene (60 ml) was heated under reflux for 
4–6 h (monitored by TLC in petroleum ether – EtOAc 50:1). The reaction mixture was 
cooled down to room temperature, sat aq NaHCO3 solution (50 ml) was added, and the mix-
ture was stirred for 5 h. The toluene phase was then separated and concentrated. Chroma-
tography (petroleum ether – EtOAc 100:1) of residue provided compound 6. 
Yield:  2.4 g (95%), colorless syrup 
Rf:  0.32 (PE:EtOAc 50:1) 
[α]
D
21
:  –58.6 (c 1.0, CHCl3) 
1H NMR (300.13 MHz, CDCl3): δ 0.94–1.13 [m, 28H, 4 x CH(CH3)2], 2.28–2.55 (m, 2H, 
H-3), 3.20 (dt, 1H, 3J1',3 = 6.6 Hz, 
3J1',2' = 3.8 Hz, H-1'), 3.80 (dt, 1H, 
3J4',5'a = 9.7 Hz,
 3J4',5'b 
= 4.0 Hz, 3J3',4' = 3.6 Hz, H-4'), 3.91–3.99 (m, 1H, H-5'a), 4.15–4.22 (m, 1H, H-5'b), 4.24–
4.28 (m, 1H, H-2'), 4.94 (dd, 1H, 3J3',4' = 3.7 Hz, 
3J2',3' = 1.6 Hz, H-3'), 5.11–5.28 (m, 2H, H-
1), 5.74–5.89 (m, 1H, H-2). 
13C NMR (75.47 MHz, CDCl3): δ 12.44, 13.11, 13.44, 13.61 [4 x CH(CH3)2], 16.86, 16.96, 
17.04, 17.23, 17.39 (2), 17.47, 17.54, [4 x CH(CH3)2], 38.59 (C-2'), 41.17 (C-3), 65.57 (C-
5'), 78.90 (C-1'), 84.44 (C-3'), 87.35 (C-4'), 118.02 (C-1), 133.36 (C-2). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C20H39IO4Si2 [M+Na]
+: 549.13238, found 
549.13240. 
C20H39IO4Si2 (526.60) calcd:  C 45.62 H 7.46 
 found: C 45.53 H 7.15 
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4.2.7 (6aR,8S,9aS)-8-allyl-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4] 
trioxadisilocin (7)  
A mixture of compound 6 (1.3 g, 2.5 mmol), tri-n-butyltin hydride (1.3 ml, 4.8 mmol), and 
azobisisobutyronitrile (AIBN, 98 mg, 0.6 mmol) in dry toluene (30 ml) was stirred under 
reflux for 4 h (monitored by TLC in petroleum ether – EtOAc 50:1)). The solution was fil-
tered and concentrated. The crude product was dissolved in Et2O (40 ml) and washed with 
aq 10% KF solution (15 ml), the organic phase was dried and concentrated. Chromatography 
(petroleum ether – EtOAc 80:1) afforded compound 7. 
Yield:  0.88 g (89%), colorless syrup 
[α]
D
21
:  –12.6 (c 1.0, CH2Cl2) 
Rf:  0.27 (PE:EtOAc 80:1) 
1H NMR (300.13 MHz, CDCl3): δ 0.94–1.13 [m, 28H, 4 x CH(CH3)2], 1.78–1.89 (m, 1H, 
H-2'a), 1.97–2.07 (m, 1H, H-2'b), 2.19–2.40 (m, 2H, H-3), 3.69–3.78 (m, 2H, H-4', H-5'a), 
3.99–4.09 (m, 1H, H-5'b), 4.09–4.19 (m, 1H, H-1'), 4.38 (dt, 1H, 3J2'a,3' = 7.9 Hz, 3J2'b,3' = 
3J3',4' = 4.5 Hz, H-3'), 5.04–5.14 (m, 2H, H-1), 5.74–5.89 (m, 1H, H-2). 
13C NMR (75.47 MHz, CDCl3): δ 12.55, 12.94, 13.38, 13.49 [4 x CH(CH3)2], 16.96, 17.02, 
17.12, 17.28, 17.38, 17.41 (2) 17.55 [4 x CH(CH3)2], 39.72 (C-3), 39.82 (C-2'), 63.82 (C-
5'), 73.49 (C-3'), 76.94 (C-1'), 85.92 (C-4'), 117.16 (C-1), 134.33 (C-2). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C20H40O4Si2 [M+H]
+: 401.25314, found 
401.25314; calcd for C20H40O4Si2 [M+Na]
+: 423.23573, found 423.23597. 
C20H40O4Si2 (400.70) calcd:   C 59.95 H 10.06 
 found:  C 60.03 H 9.88 
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4.2.8 (2R,3S,5S)-5-allyl-2-(hydroxymethyl)tetrahydrofuran-3-ol  (8)  
A solution of tetra-n-butylammonium fluoride trihydrate (316 mg, 1.2 mmol) in dry acetone 
(1 ml) was added dropwise at ambient temperature to a solution of 7 (0.2 g, 0.5 mmol) in 
dry acetone (5 ml). The reaction mixture was stirred for 1.5 h (monitored by TLC in petro-
leum ether – EtOAc 11:1) and then concentrated. Chromatography (EtOAc-MeOH 15:1) 
afforded compound 8. 
Yield:  0.59 g (75%), colorless syrup 
[α]
D
23
:  +35.3 (c 1.0, CHCl3) 
Rf:  0.27 (EtOAc-MeOH 15:1) 
1H NMR (300.13 MHz, CDCl3): δ 1.73 (ddd, 1H, 2J2'a,2'b = 13.2 Hz, 3J1',2'a = 9.5 Hz, 3J2'a,3' 
= 6.6 Hz, H-2'a), 1.91 (ddd, 1H, 2J2'a,2'b = 13.2 Hz, 
3J1',2'b = 5.7 Hz, 
3J2'b,3' = 2.5 Hz, H-2'b), 
2.30 (m, 2H, H-3), 3.12 (t, 1H, 3J5',OH = 5.7 Hz, OH-5'), 3.43 (d, 1H, 
3J3',OH = 3.6 Hz, OH-
3'), 3.59 (m, 2H, H-5'), 3.78 (dt, 1H, 3J4',5' = 4.9 Hz, 
3J3',4' = 3.4 Hz, H-4'), 4.15–4.25 (m, 2H, 
H-1', H-3'), 5.04–5.13 (m, 2H, H-1), 5.81 (m, 1H, H-2). 
13C NMR (75.47 MHz, CDCl3): δ 39.52 (C-3), 39.82 (C-2'), 63.12 (C-5'), 73.09 (C-3'), 
77.74 (C-1'), 86.72 (C-4'), 117.44 (C-1), 134.13 (C-2). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C8H14O3 [M+Na]
+: 181.08352, found 
181.08326. 
C8H14O3 (158.20) calcd:  C 60.74 H 8.92 
 found: C 60.48 H 8.89 
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4.2.9 3-((6aR,8S,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]-
trioxadisilocin-8-yl)propan-1-ol (9)   
Borane tetrahydrofuran complex solution (43.8 ml, 1.0 M in THF) was added during 30 min 
at 0 °C to a stirred solution of 7 (5.0 g, 12.5 mmol) in dry THF (45 ml) and stirring was 
continued for additional 3 h at 0 °C. A mixture of aq sodium hydroxide (180 ml, 3 N) and 
hydrogen peroxide (180 ml, 30%) was cautiously added at 0 °C to the reaction solution. The 
reaction mixture was warmed up to 15 °C and was stirred for another 1.5 h (monitored by 
TLC petroleum ether – EtOAc 4:1). The mixture was poured into iced water (100 ml) and 
the aqueous phase was extracted with CH2Cl2 (4 × 150 ml). The combined organic phases 
were washed with sat aq NaCl (100 ml), dried and concentrated. Chromatography (petro-
leum ether – EtOAc 4:1) afforded compound 9. 
Yield:  3.81 g (73%), colorless syrup 
[α]
D
21
:  – 22.0 (c 1.0, CH2Cl2) 
Rf:  0.24 (PE:EtOAc 4:1) 
1H NMR (500.13 MHz, CDCl3): δ 0.96–1.13 [m, 28H, 4 x CH(CH3)2], 1.55–1.70 (m, 4H, 
H-2, H-3), 1.81 (m, 1H, H-2'a), 2.04 (m, 1H, H-2'b), 2.11 (br s, 1H, OH-1), 3.61–3.70 (m, 
2H, H-1), 3.70–3.77 (m, 2H, H-5'a, H-4'), 3.98–4.05 (m, 1H, H-5'b), 4.05–4.13 (m, 1H, H-
1'), 4.36–4.43 (m, 1H, H-3'). 
13C NMR (62.89 MHz, CDCl3): δ 12.54, 12.95, 13.36, 13.48 [4 x CH(CH3)2], 16.95, 17.03, 
17.11, 17.26, 17.36, 17.40 (2), 17.54 [4 x CH(CH3)2], 29.42, 32.28 (C-2, C-3), 40.65 (C-2'), 
62.77 (C-1), 63.85 (C-5'), 73.68 (C-3'), 77.84 (C-1'), 86.19 (C-4'). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C20H42O5Si2 [M+H]
+: 419.26435, found 
419.26415; calcd for C20H42O5Si2 [M+Na]
+: 441.24630, found 441.24613. 
C20H42O5Si2 (418.72) calcd:    C 57.37 H 10.11 
 found:   C 57.03 H 9.97 
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4.2.10  3-((6aR,8S,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]-
trioxadisilocin-8-yl)propyl methanesulfonate (10)  
Methanesulfonyl chloride (0.22 ml, 2.8 mmol) was added dropwise at 0 °C to a stirred solu-
tion of 9 (0.5 g, 1.2 mmol) and trimethylamine (0.9 ml, 6.5 mmol) in dry CH2Cl2 (7 ml). 
After stirring for 20 min (monitored by TLC in petroleum ether – EtOAc 1:1), the mixture 
was diluted with CH2Cl2 (40 ml). The organic phase was washed with iced water (2 x 30 
ml), sat aq NaHCO3 (30 ml), and sat aq NaCl (30 ml) dried, and concentrated. Chromatog-
raphy (petroleum ether – EtOAc 4:1) afforded compound 10. 
Yield:  0.55 g (93%), colorless syrup 
[α]
D
25
:  –15.7 (c 1.0, CHCl3) 
Rf:  0.3 (PE:EtOAc 3:1) 
1H NMR (500.13 MHz, CDCl3): δ 0.88–1.12 [m, 28H, 4 x CH(CH3)2], 1.56–1.95 (m, 5H, 
H-2'a, H-2, H-3), 2.00–2.09 (m, 1H, H-2'b), 3.01 (s, 3H, SO2CH3), 3.69–3.75 (m, 2H, H-4', 
H-5'a), 3.99–4.04 (m, 1H, H-5'b), 4.04–4.12 (m, 1H, H-1'), 4.22–4.30 (m, 2H, H-1), 4.34–
4.42 (m, 1H, H-3'). 
13C NMR (125.76 MHz, CDCl3): δ 12.54, 12.93, 13.35, 13.49 [4 x CH(CH3)2], 16.95, 17.02, 
17.11, 17.27, 17.37, 17.40 (2), 17.54 [4 x CH(CH3)2], 25.75, 31.32 (C-2, C-3), 37.37 
(SO2CH3), 40.44 (C-2'), 63.77 (C-5'), 69.94 (C-1), 73.53 (C-3'), 76.93 (C-1'), 86.09 (C-4'). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C21H44O7SSi2 [M+H]
+: 497.24190, found 
497.24204; calcd for C21H44O7SSi2 [M+Na]
+: 519.22385, found 519.22362. 
 
C21H44O7SSi2 (496.81) calcd: C 50.77 H 8.93 S 6.45 
 found: C 50.60 H 9.04 S 6.53 
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4.2.11 4-(3-((6aR,8S,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4] 
trioxadisilocin-8-yl)propyl)morpholine (11)  
Morpholine (44 µl, 0.5 mmol) was added dropwise at 0 °C to a stirred solution of 10 (40 mg, 
0.08 mmol) in dry methanol (1 ml). After stirring for 6 d at ambient temperature (monitored 
by TLC in petroleum ether – EtOAc 1:1), the mixture was concentrated. The residue was 
diluted with CH2Cl2 (7 ml) and the organic phase was washed with sat aq NaHCO3 (4 ml), 
and water (4 ml), dried and concentrated. Chromatography (petroleum ether – EtOAc 1:1) 
afforded compound 11. 
Yield:  37.7 mg (96%), colorless syrup 
[α]
D
23
:  –16.6 (c 1.0, CHCl3) 
Rf:  0.15 (PE:EtOAc 1:1) 
1H NMR (500.13 MHz, CDCl3): δ 0.88–1.10 [m, 28H, 4 x CH(CH3)2], 1.45–1.63 (m, 4H, 
H-2, H-3), 1.74–1.81 (m, 1H, H-2'a), 1.99–2.04 (m, 1H, H-2'b), 2.34 (t, 2H, 3J1,2 = 7.11 Hz, 
H-1), 2.42 (br. s., 4H, CH2NCH2), 3.69–3.73 (m, 6H, H-5'a, H-4', CH2OCH2), 3.97–4.07 (m, 
2H, H-5'b, H-1'), 4.35–4.38 (m, 1H, H-3'). 
13C NMR (125.76 MHz, CDCl3): δ 12.56, 12.94, 13.37, 13.49 [4 x CH(CH3)2], 16.96, 17.03, 
17.12, 17.27, 17.37, 17.40, 17.42, 17.54 [4 x CH(CH3)2], 22.87, 33.34 (C-2, C-3), 40.56 (C-
2'), 53.69 (2) (CH2NCH2), 58.85 (C-1), 64.06 (C-5'), 66.99 (2) (CH2OCH2), 73.86 (C-3'), 
77.59 (C-1'), 85.96 (C-4'). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C24H49NO5Si2 [M+H]
+: 488.3222, found 
488.32199. 
C24H49NO5Si2 (487.83) calcd: C 59.09   H 10.12 N 2.87 
 found: C 58.87   H 10.05 N 2.76 
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4.2.12 N-(3-((6aR,8S,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4] 
trioxadisilocin-8-yl)propyl)cyclohexanamine (12)  
Cyclohexylamine (325.2 µl, 2.82 mmol) was added dropwise at 0 °C to a stirred solution of 
10 (70 mg, 0.14 mmol) in dry methanol (1 ml). After stirring for 6 d at ambient temperature 
(monitored by TLC in petroleum ether – EtOAc 3:1), the mixture was concentrated. The 
residue was diluted with CH2Cl2 (7 ml) and the organic phase was washed with sat aq Na-
HCO3 (4 ml), and water (4 ml), dried, and concentrated. Chromatography (EtOAc – MeOH 
10:1) afforded compound 12. 
Yield:  58 mg (83%), colorless syrup 
[α]
D
25
:  –17.1 (c 1.0, CHCl3) 
Rf:  0.11 (EtOAc:MeOH 10:1) 
1H NMR (300.13 MHz, CDCl3): δ 0.84–1.32 [m, 34H, 4 x CH(CH3)2, 3 x CH2Cyclohexyl], 
1.40–1.66 (m, 4H, H-2, H-3), 1.66–1.81 (m, 3H, H-2'a, CH2Cyclohexyl), 1.82–1.94 (m, 2H, 
CH2Cyclohexyl)  1.95–2.13 (m, 1H, H-2'b), 2.32–2.54 (m, 1H, CHCyclohexyl), 2.55–2.72 (m, 2H, 
H-1), 3.64–3.78 (m, 2H, H-5'a, H-4'), 3.92–4.10 (m, 2H, H-5'b, H-1'), 4.31–4.41 (m, 1H, H-
3'). 
13C NMR (75.47 MHz, CDCl3): δ 12.52, 12.91, 13.34, 13.45 [4 x CH(CH3)2], 16.93, 17.01, 
17.09, 17.25, 17.37 (3), 17.51 [4 x CH(CH3)2], 25.02 (2) (2 x CH2Cyclohexyl), 26.43, 33.32 (C-
2, C-3), 33.32 (2) (2 x CH2Cyclohexyl), 40.46 (C-2'), 46.72 (C-1), 56.77 (CHCyclohexyl) 63.98 (C-
5'), 73.77 (C-3'), 77.61 (C-1'), 85.92 (C-4'). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C26H53NO4Si2 [M+H]
+: 500.35859, found 
500.35869. 
C26H53NO4Si2 (499.88) calcd: C 62.47   H 10.69 N 2.80 
 found: C 62.37   H 10.72 N 2.78 
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4.2.13 N-(3-((6aR,8S,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4] 
trioxadisilocin-8-yl)propyl)aniline (13)  
Aniline (202 µl, 2.2 mmol) was added dropwise at 0 °C to a stirred solution of 10 (73 mg, 
0.15 mmol) in dry methanol (1 ml). After stirring for 5 d at ambient temperature (monitored 
by TLC in petroleum ether – EtOAc 3:1), the mixture was concentrated. The residue was 
diluted with CH2Cl2 (7 ml) and the organic phase was washed with sat aq NaHCO3 (4 ml), 
and water (4 ml) dried, and concentrated. Chromatography (petroleum ether – EtOAc 10:1) 
afforded compound 13. 
Yield:  54 mg (75%), light-yellow syrup 
[α]
D
23
:  –23.2 (c 1.0, CHCl3) 
Rf:  0.46 (PE:EtOAc 10:1) 
1H NMR (300.13 MHz, CDCl3): δ 0.82–1.19 [m, 28H, 4 x CH(CH3)2], 1.54–1.86 (m, 5H, 
H-2, H-3, H-2'a), 1.99–2.10 (m, 1H, H-2'b), 3.15 (t, 2H, 3J1,2 = 6.61 Hz, H-1), 3.61–3.88 (m, 
2H, H-4', H-5'a), 3.96–4.16 (m, 2H, H-1', H-5'b), 4.35–4.46 (m, 1H, H-3'), 6.58–6.73 (m, 
3H, 3 x HPhenyl), 7.12–7.23 (m, 2H, 2 x HPhenyl). 
13C NMR (75.47 MHz, CDCl3): δ 12.54, 12.94, 13.37, 13.48 [4 x CH(CH3)2], 16.96, 17.03, 
17.12, 17.28, 17.38, 17.41(2), 17.54 [4 x CH(CH3)2], 25.83, 33.02 (C-2, C-3), 40.58 (C-2'), 
43.86 (C-1), 63.94 (C-5'), 73.72 (C-3'), 77.47 (C-1'), 86.03 (C-4'), 112.70(2), 117.12, 129.19 
(2) (5 x CPhenyl), 148.38 (CquartPhenyl). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C26H47NO4Si2 [M+H]
+: 494.30728, found 
494.30719. 
C26H47NO4Si2 (493.84) calcd: C 63.24   H 9.59 N 2.84 
 found: C 63.35   H 9.42 N 2.72 
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4.2.14 N-(3-((6aR,8S,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4] 
trioxadisilocin-8-yl)propyl)-1H-benzo[d]imidazol-2-amine (14)  
2-Aminobenzimidazole (474 mg, 0.14 mmol) was added in few portions at 0 °C to a stirred 
solution of 10 (71 mg, 0.15 mmol) in dry methanol (2 ml). After stirring for 10 d at ambient 
temperature (monitored by TLC in petroleum ether – EtOAc 3:1), the mixture was concen-
trated. The residue was diluted with CH2Cl2 (7 ml) and the organic phase was washed with 
sat aq NaHCO3 (4 ml), and water (4 ml) dried and concentrated. Chromatography (EtOAc – 
MeOH 7:1) afforded 14. 
Yield:  54 mg (75%), light-yellow syrup 
[α]
D
24
:  –35.6 (c 1.0, CHCl3) 
Rf:  0.41 (EtOAc:MeOH 10:1) 
1H NMR (300.13 MHz, CDCl3): δ 0.84–1.10 [m, 28H, 4 x CH(CH3)2], 1.44–1.69 (m, 2H, 
H-3), 1.76–1.97 (m, 2H, H-2a, H-2'a), 1.99–2.10 (m, 2H, H-2b, H-2'b), 3.73–3.88 (m, 2H, 
H-5'a, H-4'), 3.97–4.13 (m, 2H, H-5'b, H-1), 4.12–4.22 (m, 1H, H-1'), 4.35–4.43 (m, 1H, H-
3'), 6.99–7.18, 7.41–7.44 (m, 4H, 4 x HAryl). 
13C NMR (75.47 MHz, CDCl3): δ 12.49, 12.97, 13.27, 13.46 [4 x CH(CH3)2], 16.91, 17.01, 
17.06, 17.20, 17.36, 17.39, 17.42, 17.54 [4 x CH(CH3)2], 26.36 (C-2), 30.75 (C-3), 40.35 
(C-2'), 42.21 (C-1), 62.81 (C-5'), 72.38 (C-3'), 79.05 (C-1'), 86.35 (C-4'), 107.57, 116.19, 
119.47, 121.33 (4 x CHAryl), 134.03, 141.99 (2 x CquartAryl), 154.08 (HNCNNH). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C27H47N3O4Si2 [M+H]
+: 534.31779, found 
534.31761. 
C27H47N3O4Si2 (533.86) calcd: C 60.75   H 8.87 N 7.87 
 found: C 60.35   H 8.42 N 7.53 
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4.2.15 N1-(3-((6aR,8S,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4] 
trioxadisilocin-8-yl)propyl)ethan-1,2-diamine (15)  
Ethane-1,2-diamine (20 ml, 0.3 mmol) was added dropwise at 0 °C to a stirred solution of 
10 (2.8 g, 5.6 mmol) in dry methanol (30 ml). After stirring for 22 h at ambient temperature 
(monitored by TLC in EtOAc – MeOH 5:1 with 1% NEt3), the mixture was concentrated. 
The residue was diluted with CH2Cl2 (7 ml) and the organic phase was washed with sat aq 
NaHCO3 (4 ml), and water (4 ml) dried and concentrated. Chromatography (EtOAc – MeOH 
3:1 with 1% NEt3) afforded 15. 
Yield:  2.5 g (95%), light-yellow syrup 
[α]
D
25
:  –14.5 (c 1.0, CH2Cl2) 
Rf:  0.15 (EtOAc:MeOH 3:1 with 1% NEt3) 
1H NMR (500.13 MHz, CDCl3): δ 0.88–1.12 [m, 28H, 4 x CH(CH3)2], 1.27 (br s, 3H, NH, 
NH2), 1.41–1.53 (m, 2H, H-5), 1.47–1.53 (m, 2H, H-4), 1.65–1.72 (m, 1H, H-2'a), 1.91–1.96 
(m, 1H, H-2'b), 2.52–2.58 (m, 2H, H-3), 2.56–2.59 (m, 2H, H-2), 2.76– 2.82 (m, 2H, H-1), 
3.60-3.65 (m, 2H, H-5'a, H-4'), 3.92-3.99 (m, 2H, H-5'b, H-1'), 4.26-4.31 (m, 1H, H-3'). 
13C NMR (125.76 MHz, CDCl3): δ 12.54, 12.94, 13.36, 13.48 [4 x CH(CH3)2], 16.95, 17.02, 
17.11, 17.27, 17.37, 17.39, 17.40, 17.53 [4 x CH(CH3)2], 26.41 (C-4), 33.24 (C-5), 40.56 
(C-2'), 41.75 (C-1), 49.72 (C-3), 52.49 (C-2), 64.05 (C-5'), 73.85 (C-3'), 77.65 (C-1'), 85.97 
(C-4'). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C22H48N2O4Si2 [M+H]
+: 461.32254, found 
461.32271; calcd for C22H48N2O4Si2 [M+Na]
+: 483.30448, found 483.30472. 
C22H48N2O4Si2 (460.80) calcd: C 57.34   H 10.50 N 6.08 
 found: C 56.75   H 10.40 N 5.93 
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4.2.16  (2R,3S,5S)-5-(3-((2-aminoethyl)amino)propyl)-2-(hydroxymethyl)tetra-hydro-
furan-3-ol (16)  
A solution of tetra-n-butylammonium fluoride trihydrate (0.5 g, 2 mmol) in dry acetone (2 
ml) was added dropwise at ambient temperature to a solution of 15 (0.6 g, 1.3 mmol) in dry 
acetone (5 ml). The reaction mixture was stirred for 1.5 h (monitored by TLC in EtOAc – 
MeOH 5:2 with 1% NEt3) and then concentrated. Chromatography (EtOAc – MeOH 1:1 
with 1% NEt3) afforded compound 16. 
Yield:  0.2 g (90%), light-yellow syrup 
[α]
D
24 :  –24.5 (c 1.0, CHCl3)  
Rf:  0.0 (EtOAc:MeOH 3:1 with 1% NEt3) 
1H NMR (300.13 MHz, CDCl3): δ 1.43–1.63 (m, 2H, H-3), 1.47–1.65 (m, 2H, H-4), 1.65–
1.76 (m, 1H, H-2'a), 1.88–1.99 (m, 1H, H-2'b), 2.55–2.66 (m, 4H, H-5, H-2), 2.71–2.79 (m, 
2H, 3J1ab,2ab = 5.77 Hz, 
3J1ab,2ab = 5.93 Hz, H-1), 3.47 (dd, 1H, 
2J5'a,5'b = 11.14 Hz, H-5'a), 3.64 
(d´t`, 1H, 3J4',5' = 4.15 Hz, 
2J5'a,5'b = 11.14 Hz, H-5'b), 3.75 (d´t`, 1H, 
3J4',5'b  = 4.15 Hz, 
3J3',4' = 
3J4',5'a = 7.2 Hz, H-4'), 3.99–4.12 (m, 1H, H-1'), 4.25 (dt, 1H, 3J3',4' = 7.2 Hz, H-3'). 
13C NMR (75.47 MHz, CDCl3): δ 26.45 (C-4), 33.41 (C-3), 40.37 (C-2'), 41.33 (C-1), 49.51 
(C-5), 52.14 (C-2), 63.44 (C-5'), 73.30 (C-3'), 77.84 (C-1'), 87.11 (C-4'). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C10H22N2O3 [M+H]
+: 219.16728, found 
219.16721. 
C10H22N2O3 (218.30) calcd: C 55.02   H 10.16 N 12.83 
 found: C 54.78   H 10.29 N 12.96 
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4.2.17 (6aR,8S,9aS)-8-(3-azidopropyl)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-
f][1,3,5,2,4]trioxadisilocine (17)  
Sodium azide (3.4 g, 52.3 mmol) was added at ambient temperature to a solution of 10 (2.35 
g, 4.7 mmol) in dry DMF (25 ml). The reaction mixture was stirred for 24 h (monitored by 
TLC in petroleum ether – EtOAc 20:1) and then the mixture was diluted with EtOAc (30 ml). 
The organic phase was washed with iced water (2 x 30 ml), dried and concentrated. Chro-
matography (petroleum ether – EtOAc 50:1) afforded compound 17. 
Yield:  2.02 g (96%), colorless syrup 
[α]
D
23
:  –38.8 (c 1.0, CHCl3) 
Rf:  0.32 (PE:EtOAc 50:1) 
1H NMR (300.13 MHz, CDCl3): δ 0.87–1.16 [m, 28H, 4 x CH(CH3)2], 1.55–1.74 (m, 4H, 
H-2, H-3), 1.74–1.83 (m, 1H, H-2'a), 2.00–2.08 (m, 1H, H-2'b), 3.24–3.37 (m, 2H, H-1), 
3.68–3.76 (m, 2H, H-5'a, H-4'), 3.99–4.11 (m, 2H, H-5'b, H-1'), 4.35–4.41 (m, 1H, H-3'). 
13C NMR (75.47 MHz, CDCl3): δ 12.55, 12.95, 13.38, 13.49 [4 x CH(CH3)2], 16.96, 17.04, 
17.12, 17.28, 17.38, 17.41(2), 17.55 [4 x CH(CH3)2], 25.40 (C-2), 32.56 (C-3), 40.55 (C-2'), 
51.40 (C-1), 63.93 (C-5'), 73.70 (C-3'), 77.12 (C-1'), 86.08 (C-4'). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C20H41N3O4Si2 [M+H]
+: 444.27084, found 
444.27107; calcd for C20H41N3O4Si2 [M+Na]
+: 466.25278, found 466.25291. 
C20H41N3O4Si2 (443.74) calcd: C 54.14 H 9.31 N 9.47 
 found: C 54.18 H 9.19 N 9.12 
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4.2.18 4-phenyl-1-(3-((6aR,8S,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-
f][1,3,5,2,4]trioxadisilocin-8-yl)propyl)-1H-1,2,3-triazole (18)  
A mixture of compound 17 (0.1 g, 0.23 mmol), copper(II) sulfate pentahydrate (2 mg, 0.08 
mmol), L(+)-ascorbic acid (10 mg, 0.06 mmol) and phenylacetylene (50 µl, 0.46 mmol) in 
water/DMF (1.5 ml/0.5 ml) was stirred for 63 h at 75 °C (monitored by TLC in petroleum 
ether – EtOAc 20:1). The solution was filtered and concentrated. Chromatography (petro-
leum ether – EtOAc 3:1) afforded compound 18. 
Yield:  102 mg (83%), light-yellow syrup 
[α]
D
23
:  –17.9 (c 1.0, CHCl3) 
Rf:  0.42 (PE:EtOAc 3:1) 
1H NMR (300.13 MHz, CDCl3): δ 0.84–1.12 [m, 28H, 4 x CH(CH3)2], 1.53–1.63 (m, 2H, 
H-3), 1.73–1.82 (m, 1H, H-2'a), 2.00–2.18 (m, 3H, H-2, H-2'b), 3.69–3.78 (m, 2H, H-5'a, H-
4'), 3.99–4.16 (m, 2H, H-5'b, H-1'), 4.34–4.40 (m, 1H, H-3'), 4.42–4.53 (m, 2H, H-1), 7.30–
7.46 (m, 3H, 3 x HPhenyl), 7.77 (s, 1H, CH=C), 7.81–7.85 (m, 2H, 2 x HPhenyl). 
13C NMR (75.47 MHz, CDCl3): δ 12.52, 12.89, 13.34, 13.46 [4 x CH(CH3)2], 16.94, 17.02, 
17.09, 17.25, 17.34, 17.38, 17.39, 17.53 [4 x CH(CH3)2], 26.97 (C-2), 32.21 (C-3), 40.41 
(C-2'), 50.22 (C-1), 63.68 (C-5'), 73.36 (C-3'), 77.03 (C-1'), 86.10 (C-4'), 119.55 (CH=C), 
125.67 (2), 128.05, 128.79 (2) (CPhenyl), 130.71 (CquartPhenyl), 147.70 (CH=C). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C28H47N3O4Si2 [M+H]
+: 546.31779, found 
546.31738; calcd for C28H47N3O4Si2 [M+Na]
+: 568.29973, found 568.29927. 
C28H47N3O4Si2 (545.87) calcd: C 61.61 H 8.68 N 7.70 
 found: C 61.49 H 8.78 N 7.59 
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4.2.19 3-((6aR,8S,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4] 
trioxadisilocin-8-yl)propan-1-amine (19)  
Palladium on carbon 10 wt. % (0.4 g, 3.8 mmol) was added to a stirred solution of 17 (1.7 g, 
3.8 mmol) in dry methanol (20 ml). After stirring for 24 h at ambient temperature (monitored 
by TLC in EtOAc – MeOH 1:1 with 1% NEt3), The solution was filtered and concentrated. 
Chromatography (EtOAc – MeOH 1:1 with 1% NEt3) afforded compound 19. 
Yield:  0.9 g (56%), brown-yellow syrup 
[α]
D
22
:  –17.1 (c 1.0, MeOH) 
Rf:  0.26 (EtOAc:MeOH 1:1 with 1% NEt3) 
1H NMR (300.13 MHz, CDCl3): δ 0.81–1.13 [m, 28H, 4 x CH(CH3)2], 1.41–1.63 (m, 4H, 
H-2, H-3), 1.65–1.89 (m, 1H, H-2'a), 1.94–2.05 (m, 1H, H-2'b), 2.71 (br s, 2H, H-1), 3.67–
3.78 (m, 2H, H-5'a, H-4'), 3.98–4.08 (m, 2H, H-5'b, H-1'), 4.33–4.39 (m, 1H, H-3'). 
13C NMR (75.47 MHz, CDCl3): δ 12.51, 12.91, 13.34, 13.46 [4 x CH(CH3)2], 16.93, 17.00, 
17.09, 17.24, 17.35, 17.38 (2), 17.51 [4 x CH(CH3)2], 29.83 (C-2), 32.78 (C-3), 40.53 (C-
2'), 42.03 (C-1), 63.95 (C-5'), 73.74 (C-3'), 77.57 (C-1'), 85.95 (C-4'). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C20H43NO4Si2 [M+H]
+: 418.28034, found 
418.28017; calcd for C20H43NO4Si2 [M+Na]
+: 440.26228, found 440.26176. 
C20H43NO4Si2 (417.74) calcd: C 57.51 H 10.38 N 3.35 
 found: C 58.04 H 10.28 N 3.19 
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4.2.20 1-phenyl-N-(3-((6aR,8S,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f] 
[1,3,5,2,4]trioxadisilocin-8-yl)propyl)methanimine (20)  
A mixture of compound 19 (0.1 g, 0.24 mmol), benzaldehyde (25 µl, 0.25 mmol), molecular 
sieve powder (20 mg, A3 and A4) in dry methanol (1 ml) was stirred for 40 h at ambient 
temperature. The solution was filtered and concentrated without further purification to give 
compound 20. 
Yield:  115 mg (95%), brown-yellow syrup 
[α]
D
24
:  –13.1 (c 1.0, CHCl3) 
Rf:  0.38 (PE:EtOAc 5:1) 
1H NMR (300.13 MHz, CDCl3): δ 0.83–1.19 [m, 28H, 4 x CH(CH3)2], 1.43–1.92 (m, 5H, 
H-2, H-3, H-2'a), 1.96–2.11 (m, 1H, H-2'b) 3.55–3.66 (m, 2H, H-1), 3.67–3.79 (m, 2H, H-
4', H-5'a), 3.95–4.19 (m, 2H, H-1', H-5'b), 4.30–4.43 (m, 1H, H-3'), 7.32–7.50, 7.66–7.74 
(m, 5H, 5 x HPhenyl), 8.28 (s, 1H, NCH). 
13C NMR (75.47 MHz, CDCl3): δ 12.55, 12.93, 13.38, 13.49 [4 x CH(CH3)2], 16.97, 17.04, 
17.13, 17.28, 17.38, 17.41 (2), 17.55 [4 x CH(CH3)2], 27.09 (C-2), 33.24 (C-3), 40.52 (C-
2'), 61.49 (C-1), 64.04 (C-5'), 73.85 (C-3'), 77.63 (C-1'), 85.93 (C-4'), 128.02 (2), 128.54 (2), 
130.47 (5 x CPhenyl), 136.28 (CquartPhenyl), 161.01 (NCH). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C27H47NO4Si2 [M+H]
+: 506.31164, found 
506.31112. 
C27H47NO4Si2 (505.85) calcd: C 64.11 H 9.37 N 2.77 
 found: C 64.42 H 9.08 N 2.73 
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4.2.21 1-(pyridin-2-yl)-N-(3-((6aR,8S,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo 
[3,2-f][1,3,5,2,4]trioxadisilocin-8-yl)propyl)methanimine (21)  
Compound 19 (0.1 g, 0.24 mmol), pyridine-2-carbaldehyde (25 µl, 0.25 mmol) and molec-
ular sieve powder (20 mg, A3 and A4) in dry methanol (1 ml) was stirred for 40 h at ambient 
temperature. The solution was filtered and concentrated without further purification to give 
compound 21. 
Yield:  109 mg (90%), brown-yellow syrup 
[α]
D
24
:  –12.5 (c 1.0, CHCl3) 
Rf:  0.35 (PE:EtOAc 3:1) 
1H NMR (250.13 MHz, CDCl3): δ 0.79–1.19 [m, 28H, 4 x CH(CH3)2], 1.20–2.09 (m, 6H, 
H-2, H-3, H-2'), 3.45–3.80 (m, 4H, H-1, H-4', H-5'a), 3.84–4.15 (m, 2H, H-1', H-5'b), 4.15–
4.53 (m, 1H, H-3'), 7.06–8.01 (m, 3H, 3 x HPyridine), 8.37 (s, 1H, NCH), 8.46–8.68 (m, 1H, 
HPyridine). 
13C NMR (62.89 MHz, CDCl3): δ 12.53, 12.92, 13.36, 13.47 [4 x CH(CH3)2], 16.95, 17.02, 
17.11, 17.26, 17.39 (3), 17.53 [4 x CH(CH3)2], 26.90, 33.19 (C-2, C-3), 40.51 (C-2'), 61.26 
(C-1), 64.02 (C-5'), 73.83 (C-3'), 77.20 (C-1'), 85.94 (C-4'), 121.18, 124.61, 136.49, 149.37 
(4 x CPyridine), 154.56 (CquartPyridine), 161.95 (NCH). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C26H46N2O4Si2 [M+H]
+: 507.30689, found 
507.30739. 
C26H46N2O4Si2 (506.83) calcd: C 61.62 H 9.15 N 5.53 
 found: C 61.15 H 8.99 N 5.35 
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4.2.22 3-((6aR,8S,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4] 
trioxadisilocin-8-yl)propyl acetate (22)  
Freshly distilled Ac2O (7.5 ml) was added dropwise at 0 °C to a vigorously stirred solution 
of 9 (2.3 g, 5.5 mmol) in dry pyridine (15 ml). The mixture was allowed to attain ambient 
temperature and stirring was continued overnight. TLC (in petroleum ether – EtOAc 5:1 
with 1% NEt3) showed then that the reaction was complete. Excess of Ac2O was then de-
stroyed by addition of methanol (5 ml) at 0 °C and stirring was continued for additional 30 
min. The mixture was poured into iced water and the aqueous phase was extracted with 
CH2Cl2 (3 × 40 ml). The combined organic phases were successively washed with aq 15% 
NaHSO4 (3 × 40 ml), ice water (40 ml), and sat aq NaHCO3 solution (2 × 40 ml), then dried 
and concentrated. Chromatography (petroleum ether – EtOAc 5:1) gave the compound 22. 
Yield:  2.18 g (86%), colorless syrup 
[α]
D
22
:  –20.5 (c 1.0, CH2Cl2) 
Rf:  0.57 (PE:EtOAc 5:1) 
1H NMR (250.13 MHz, CDCl3): δ 0.97–1.13 (m, 28H, 4 x CH(CH3)2), 1.54–1.80 (m, 5H, 
H-3, H-2, H-2'a), 1.99–2.08 (m, 1H, H-2'b), 2.04 (s, 3H, COCH3), 3.67–3.76 (m, 2H, H-5'a, 
H-4'), 3.98–4.12 (m, 4H, H-1', H-5'b, H-1), 4.38 (ddd, 1H, 3J3',4' = 4.1 Hz, 3J3',2'b = 4.3 Hz, 
3J3',2'a = 8.1 Hz, H-3'). 
13C NMR (62.89 MHz, CDCl3): δ 12.54, 12.94, 13.38, 13.49 [4 x CH(CH3)2], 16.96, 17.03, 
17.12, 17.28, 17.38, 17.41 (2), 17.54 [4 x CH(CH3)2], 20.94 (COCH3), 25.05 (C-2), 31.89 
(C-3), 40.49 (C-2'), 63.93 (C-5'), 64.36 (C-1) 73.72 (C-3'), 77.21 (C-1'), 86.03 (C-4'), 171.12 
(COCH3). 
29Si NMR (99.35 MHz, CDCl3): δ –12.8, –15.5. 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C22H44O6Si2 [M+H]
+: 461.27492, found 
461.27531; calcd for C22H44O6Si2 [M+Na]
+: 483.25686, found 483.25706. 
C22H44O6Si2 (460.76) calcd: C 57.35 H 9.63 
 found: C 57.31 H 9.45 
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4.2.23 3-((2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)propyl 
acetate (23)  
A solution of tetra-n-butylammonium fluoride trihydrate (1.5 g, 5.7 mmol) in dry acetone (5 
ml) was added dropwise at ambient temperature to a solution of 22 (1.5 g, 3.3 mmol) in dry 
acetone (25 ml). The reaction mixture was stirred for 1.5 h at ambient temperature (moni-
tored by TLC in EtOAc) and then concentrated. Chromatography (EtOAc – MeOH 15:1) 
afforded compound 23. 
Yield:  683 mg (96%), colorless syrup 
[α]
D
22
:  +18.5 (c 1.0, MeOH) 
Rf:  0.43 (EtOAc:MeOH 15:1) 
1H NMR (250.13 MHz, CDCl3): δ 1.56–1.77 (m, 5H, H-2, H-3, H-2'a), 1.92–1.99 (m, 1H, 
H-2'b), 2.05 (s, 3H, COCH3), 2.38 (br s, 1H, OH-5'), 2.47 (br s, 1H, OH-3'), 3.58–3.68 (m, 
2H, H-5'), 3.79–3.84 (m, 1H, H-4'), 4.06–4.13 (m, 2H, H-1), 4.13–4.21 (m, 1H, H-1'), 4.29 
(m, 1H, H-3'). 
13C NMR (62.89 MHz, CDCl3): δ 20.96 (COCH3), 25.25 (C-2), 31.64 (C-3), 41.35 (C-2'), 
63.19 (C-5'), 64.30 (C-1) 73.37 (C-3'), 78.11 (C-1'), 86.78 (C-4'), 171.33 (COCH3). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C10H18O5 [M+Na]
+: 241.10464, found 
241.10499. 
C10H18O5 (218.25) calcd: C 55.03 H 8.31 
 found: C 52.60 H 8.28 
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4.2.24 (2R,3S,5S)-5-(3-acetoxypropyl)-2-((pivaloyloxy)methyl)tetrahydrofuran-3-yl 
pivalate (24)  
Pivaloyl chloride (10 ml, 0.08 mmol) and 4-(dimethylamino)pyridine (20 mg, 0.16 mmol) 
was added to a solution of 23 (1.0 g, 4.6 mmol) in dry DMF (25 ml). The reaction mixture 
was stirred for 4 h (monitored by TLC in Tol – EtOAc 3:1) and then the mixture was con-
centrated and finally diluted with sat aq NaHCO3 solution (30 ml). The aqueous phase was 
extracted with CH2Cl2 (4 x 50 ml), dried and concentrated. Chromatography (petroleum 
ether – EtOAc 10:1) afforded compound 24. 
Yield:  1.7 g (95%), colorless syrup 
[α]
D
22
:  +17.3 (c 1.0, CH2Cl2) 
Rf:  0.57 (Tol:EtOAc 3:1) 
1H NMR (300.13 MHz, CDCl3): δ 1.20, 1.21 [2 x s, 18H, 2 x C(CH3)3], 1.60–1.79 (m, 5H, 
H-3, H-2, H-2'a), 1.97–2.04 (m, 1H, H-2'b), 2.04 (s, 3H, COCH3), 4.00–4.05 (m, 1H, H-4'), 
4.07–4.13 (m, 3H, H-1, H-1'), 4.14–4.19 (m, 2H, H-5'), 5.07–5.13 (m, 1H, H-3'). 
13C NMR (75.46 MHz, CDCl3): δ 20.91 (COCH3), 25.24 (C-2), 26.99, 27.20 [2 x COC 
(CH3)3],  31.43 (C-3), 38.47 (C-2'), 38.54, 38.75 [2 x COC(CH3)3], 64.23 (C-1), 64.32 (C-5'), 
76.33 (C-3'), 78.55 (C-1'), 82.37 (C-4'), 171.07 (COCH3), 178.01, 178.05 [2 x COC(CH3)3]. 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C20H34O7 [M+Na]
+: 409.21967, found 
409.21949. 
C20H34O7 (386.49) calcd: C 62.16 H 8.87 
 found: C 61.87 H 8.86 
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4.2.25 (2R,3S,5S)-5-(3-hydroxypropyl)-2-((pivaloyloxy)methyl)tetrahydrofuran-3-yl 
pivalate (25)  
Acetyl chloride (0.82 ml, 11.5 mmol) was added dropwise at 0 °C to a vigorously stirred dry 
methanol (40 ml). To that methanolic HCl-solution, compound 24 (0.57 g, 1.5 mmol) was 
added. The mixture was allowed to attain ambient temperature and stirring was continued 
for 4 h (monitored by TLC in Tol – EtOAc 1:1). The reaction solution was cautiously neu-
tralized by addition of ion-exchange resins OH–, filtered and concentrated. To avoid any side 
reaction, the desired compound 25 was used for subsequent reaction without further purifi-
cation. Chromatography (Tol – EtOAc 1:1) afforded an analytical sample. 
Yield:  approx. 483 mg (95%), colorless syrup 
[α]
D
22
:  +35.5 (c 1.0, CH2Cl2) 
Rf:  0.57 (Tol:EtOAc 1:1) 
1H NMR (300.13 MHz, CDCl3): δ 1.20, 1.21 [2 x s, 18H, 2 x C(CH3)3], 1.56–1.86 (m, 5H, 
H-3, H-2, H-2'a), 2.02 (m, 1H, H-2'b), 2.18 (br s, 1H, OH), 3.61–3.74 (m, 2H, H-1), 4.03–
4.07 (m, 1H, H-4'), 4.09–4.15 (m, 1H, H-1'), 4.17–4.23 (m, 2H, H-5'), 5.07–5.12 (m, 1H, H-
3'). 
13C NMR (75.46 MHz, CDCl3): δ  27.01, 27.20 [2 x COC(CH3)3], 29.67 (C-2), 31.87 (C-3), 
38.71 (C-2'), 38.56, 38.78 [2 x COC(CH3)3], 62.65 (C-1), 64.34 (C-5'), 76.21 (C-3'), 79.25 
(C-1'), 82.58 (C-4'), 178.05, 178.13 [2 x COC(CH3)3]. 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C18H32O6 [M+Na]
+: 367.20911, found 
367.20945. 
C18H32O6 (344.45) calcd: C 62.77 H 9.36 
 found: C 61.79 H 9.45 
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4.2.26 (2R,3S,5S)-5-(3-((methylsulfonyl)oxy)propyl)-2-((pivaloyloxy)methyl) tetra-
hydrofuran-3-yl pivalate (26)  
Methanesulfonyl chloride (0.22 ml, 2.8 mmol) was added dropwise at 0 °C to a stirred solu-
tion of 25 (0.5 g, 1.5 mmol) and trimethylamine (0.9 ml, 6.5 mmol) in dry CH2Cl2 (10 ml). 
After stirring for 20 min at ambient temperature (monitored by TLC in petroleum ether – 
EtOAc 1:1), the mixture was diluted with CH2Cl2 (20 ml). The organic phase was washed 
with sat aq NaHCO3 (10 ml), and sat aq NaCl (10 ml) dried, and concentrated. Chromatog-
raphy (petroleum ether – EtOAc 3:1) afforded compound 26. 
Yield:  567 mg (91%), colorless syrup 
[α]
D
22
:  +22.7 (c 1.0, CHCl3) 
Rf:  0.57 (Tol:EtOAc 1:1) 
1H NMR (250.13 MHz, CDCl3): δ 1.20, 1.21 [2 x s, 18H, 6 x C(CH3)], 1.60–1.75 (m, 2H, 
H-3), 1.76–1.84 (m, 1H, H-2'a), 1.84–1.95 (m, 2H, H-2), 1.96–2.04 (m, 1H, H-2'b), 3.01 (s, 
3H, SO2CH3), 4.01–4.04 (m, 1H, H-4'), 4.03–4.12 (m, 1H, H-1'), 4.14–4.20 (m, 2H, H-5'), 
4.23–4.35 (m, 2H, H-1), 5.09–5.11 (m, 1H, H-3'). 
13C NMR (62.89 MHz, CDCl3): δ 26.05 (C-2), 27.01, 27.21 [2 x COC(CH3)], 30.83 (C-3), 
37.38 (SO2CH3), 38.53 (C-2'), 38.56, 38.77 [2 x COC(CH3)], 64.26 (C-5'), 69.79 (C-1), 
76.20 (C-3'), 78.33 (C-1'), 82.53 (C-4'), 178.02, 178.06 [2 x COC(CH3)]. 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C19H34O8S [M+Na]
+: 445.18666, found 
445.18686. 
C19H34O8S (422.53) calcd: C 54.01 H 8.11 S 7.59 
 found: C 54.00 H 8.02 S 7.60 
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4.2.27 (2R,3S,5S)-5-(3-((2-aminoethyl)amino)propyl)-2-((pivaloyloxy)methyl) tetra-
hydrofuran-3-yl pivalate (27)  
Ethane-1,2-diamine (0.1 ml, 1.5 mmol) was added dropwise at 0 °C to a stirred solution of 
26 (0.12 g, 0.3 mmol) in dry methanol (1.5 ml). After stirring for 20 h at ambient temperature 
(monitored by TLC in EtOAc – MeOH 10:1 with 1% NEt3), the mixture was concentrated. 
The residue was diluted with CH2Cl2 (10 ml) and the organic phase was washed with sat aq 
NaHCO3 (7 ml), and water (7 ml) dried and concentrated. Chromatography (EtOAc – MeOH 
1:1 with 1% NEt3) afforded 27. 
Yield:  88 mg (80%), light-yellow syrup 
[α]
D
22
:  –17.6 (c 1.0, CHCl3) 
Rf:  0.12 (EtOAc:MeOH 1:1 with 1% NEt3) 
1H NMR (500.13 MHz, MeOD): δ 1.20, 1.21 [2 x s, 18H, 2 x C(CH3)3], 1.55–1.77 (m, 4H, 
H-4, H-5), 1.78–1.87 (m, 1H, H-2'a), 2.03–2.10 (m, 1H, H-2'b), 2.82–2.91 (m, 2H, H-3), 
2.98–3.07 (m, 4H, H-2, H-1), 3.98–4.01 (m, 1H, H-4'), 4.06–4.20 (m, 3H, H-1', H-5'), 5.10–
5.12 (m, 1H, H-3'). 
13C NMR (125.76 MHz, MeOD): δ 25.98 (C-4), 27.37, 27.60 [2 x COC(CH3)3], 33.36 (C-5), 
39.26 (C-1), 39.49 (C-2'), 39.55, 39.84 [2 x COC(CH3)3],  48.12 (C-2), 49.69 (C-3), 65.40 
(C-5'), 77.62 (C-3'), 80.19 (C-1'), 83.94 (C-4'), 179.41, 179.67 [2 x COC(CH3)3]. 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C20H38N2O5 [M+Na]
+: 409.26729, found 
409.26733. 
C20H38N2O5 (386.53) calcd: C 62.15 H 9.91 N 7.25 
 found: C 61.83 H 9.29 N 7.03 
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4.2.28 (6aR,8R,9aS)-8-(2,3-dibromopropyl)-2,2,4,4-tetraisopropyltetrahydro-6H-furo 
[3,2-f][1,3,5,2,4]trioxadisilocine (28) 
Pyridinium tribromide (6 g, 18.8 mmol) was added in few portions to a stirred solution of 7 
(5 g, 12.5 mmol) in dry CH2Cl2 (200 ml). After stirring for 40 min at ambient temperature 
(monitored by TLC in Tol), the mixture was diluted with aq Na2S2O3 (50 ml, 1 M) and stir-
ring was continued until the brown solution was decolorized. The mixture was extracted 
with Et2O (3 × 100 ml). The organic phase was washed with sat aq NaHCO3 (100 ml), water 
(100 ml) and sat aq NaCl (100 ml) dried and concentrated. Chromatography (petroleum 
ether – EtOAc 3:1) afforded compound 28. To avoid any side reaction, the desired compound 
28 was used for subsequent reaction without further purification. 
Yield:  approx. 6.64 g (95%), brown-yellow syrup 
Rf:  0.67 (Tol) 
4.2.29 (6aR,8S,9aS)-8-(2,3-diazidopropyl)-2,2,4,4-tetraisopropyltetrahydro-6H-
furo[3,2-f][1,3,5,2,4]trioxadisilocine (29)  
Sodium azide (9 g, 0.1 mol) was added at ambient temperature to a solution of 28 (7 g, 12.5 
mmol) in dry DMF (60 ml). The reaction mixture was stirred for 2.5 h at 70 °C (monitored 
by TLC in Tol) and then the mixture was diluted with EtOAc (100 ml). The organic phase 
was washed with iced water (60 ml) and sat aq NaCl (60 ml), dried and concentrated. Chro-
matography (Tol) afforded compound 29. 
Yield:   4.5 g (75%), colorless syrup 
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[α]
D
25
:  –27.6 (c 1.0, CH2Cl2)7 
Rf:  0.44 (Tol) 
1H NMR (300.13 MHz, CDCl3) 2 diastereomers: δ 0.88–1.12 [m, 28H, 4 x CH(CH3)2], 
1.56–1.62 (m, 1H, H-3a), 1.67–1.72 (m, 1H, H-3b), 1.77–1.86 (m, 1H, H-2'a), 2.07–2.12 (m, 
1H, H-2'b), 3.30–3.46 (m, 1H, H-1a), 3.46– 3.51 (m, 1H, H-1b), 3.66-3.74 (m, 1H, H-5'a), 
3.74 (m, 1H, H-4'), 3.75-3.79 (m, 1H, H-2), 4.01-4.03 (m, 1H, H-5'b), 4.12-4.23 (m, 1H, H-
1'), 4.37-4.41 (m, 1H, H-3'). 
13C NMR (75.47 MHz, CDCl3) 2 diastereomers: δ 12.54, 12.97, 13.34, 13.47 [4 x 
CH(CH3)2], 16.94, 17.02, 17.10, 17.25, 17.37, 17.39 (2), 17.53 [4 x CH(CH3)2], 36.94, 38.13 
(C-3), 40.77, 40.82 (C-2'), 54.28, 55.35 (C-1), 59.02, 59.42 (C-2), 63.70, 63.81 (C-5'), 73.40, 
73.54 (C-3'), 73.94, 74.05 (C-1'), 86.21, 86.41 (C-4'). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C20H40N6O4Si2 [M+Na]
+: 507.25418, 
found 507.25408. 
C20H40N6O4Si2 (484.74) calcd: C 49.56   H 8.32 N 17.34 
 found: C 49.27   H 8.55 N 17.11 
     
4.2.30 1,1'-(3-((6aR,8S,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4] 
trioxadisilocin-8-yl)propane-1,2-diyl)bis(4-phenyl-1H-1,2,3-triazole) (30)  
A mixture of compound 29 (0.1 g, 0.21 mmol), copper(II) sulfate pentahydrate (4 mg, 0.16 
mmol), L(+)-ascorbic acid (25 mg, 0.15 mmol) and phenylacetylene (100 µl, 0.92 mmol) in 
water/DMF (1.5 ml/1.5 ml) was stirred for 60 h at 75 °C (monitored by TLC in Tol). The 
solution was filtered and concentrated. Chromatography (petroleum ether – EtOAc 1:1) af-
forded compound 30. 
Yield:  78 mg (55%), white amorphous solid 
                                                 
7  Optical rotation was determined although compound 29 implies a mixture of diastereomers. The same ap-
plies all the other diastereomers too. 
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[α]
D
23
:  –25.6 (c 1.0, CHCl3) 
Rf:  0.81 (PE:EtOAc 1:1) 
1H NMR (500.13 MHz, CDCl3) 2 diastereomers: δ 0.74–1.15 [m, 28H, 4 x CH(CH3)2], 
1.74–1.88 (m, 1H, H-2'a), 1.98–2.12 (m, 1H, H-2'b), 2.13–2.63 (m, 2H, H-3), 3.69–3.83 (m, 
2H, H-5'a, H-4'), 3.98–4.06 (m, 1H, H-5'b), 3.62–3.69, 4.23–4.33 (m, 1H, H-1'), 4.34–4.45 
(m, 1H, H-3'), 4.95–5.14 (m, 2H, H-1), 5.22–5.35 (m, 1H, H-2), 7.24–7.77 (m, 12H, 10 x 
HPhenyl, 2 x CH=C). 
13C NMR (125.76 MHz, CDCl3) 2 diastereomers: δ 12.51, 12.90, 13.28, 13.42 [4 x 
CH(CH3)2], 16.86, 16.91, 16.99, 17.05, 17.21, 17.36 (2), 17.49 [4 x CH(CH3)2], 38.38, 38.92 
(C-3), 40.32, 40.45 (C-2'), 52.89, 53.72 (C-1), 58.96, 59.31 (C-2), 63.44, 63.51 (C-5'), 72.98, 
73.11 (C-3'), 77.19, 73.57 (C-1'), 86.09, 86.26 (C-4'), 120.42, 120.66, 120.86, 121.67 (2 x 
CH=C), 125.71 (3), 125.75, 128.20, 128.29, 128.72 (2), 128.77 (2) (2 x 5 CPhenyl), 130.02 (2) 
(2 x CquartPhenyl), 147.48, 147.64, 147.83 (2 x CH=C). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C36H52N6O4Si2 [M+H]
+: 689.36728, found 
689.36699. 
C36H52N6O4Si2 (689.02) calcd: C 62.76 H 7.61 N 12.20 
 found: C 62.16 H 7.35 N 12.06 
4.2.31 3-((6aR,8S,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]-
trioxadisilocin-8-yl)propan-1,2-diamine (31) 
Palladium on carbon 10 wt. % (0.2 g, 0.2 mmol was added to a stirred solution of 29 (0.5 g, 
1 mmol) in dry methanol (7 ml). After stirring for 24 h at ambient temperature (monitored 
by TLC in EtOAc – MeOH 5:1 with 1% NEt3). The solution was filtered and concentrated. 
Analytical sample of 31 was achieved by chromatography (EtOAc – MeOH 1:1 with 1% 
NEt3). 
Yield:   415 mg (93%), yellow syrup 
[α]
D
23
:  –17.5 (c 1.0, CH2Cl2) 
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Rf:  0.0 (EtOAc:MeOH 1:1 with 1% NEt3) 
1H NMR (500.13 MHz, MeOD) 2 diastereomers: δ 0.97–1.12 [m, 28H, 4 x CH(CH3)2], 
1.44–1.73 (m, 1H, H-3), 1.82–1.91 (m, 1H, H-2'a), 2.02–2.10 (m, 1H, H-2'b), 2.50–2.56 (m, 
1H, H-1a), 2.67–2.75 (m, 1H, H-1b), 2.88–2.93 (m, 1H, H-2),  3.67–3.78 (m, 2H, H-5'a, H-
4') 3.98–4.04 (m, 1H, H-5'b), 4.16–4.26 (m, 1H, H-1'), 4.38–4.44 (m, 1H, H-3'). 
13C NMR (125.76 MHz, MeOD) 2 diastereomers: δ 14.01, 14.35, 14.74, 14.86 [4 x 
CH(CH3)2], 17.62, 17.67, 17.74, 17.90, 18.03 (2), 18.16 [4 x CH(CH3)2], 41.23, 41.51 (C-
3), 42.22, 42.52 (C-2'), 48.38, 48.68 (C-1), 51.81, 53.14 (C-2), 65.28, 65.48 (C-5'), 75.40, 
75.49 (C-3'), 76.48, 78.07 (C-1'), 87.76, 88.03 (C-4'). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C20H44N2O4Si2 [M+H]
+: 433.29124, found 
433.29152. 
C20H44N2O4Si2 (432.75) calcd: C 55.51 H 10.25 N 6.47 
 found: C 54.36 H 10.22 N 6.32 
4.2.32  N,N'-(3-((6aR,8S,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5, 
2,4]trioxadisilocin-8-yl)propane-1,2-diyl)diacetamide (32) 
Freshly distilled Ac2O (1.5 ml) was added dropwise at 0 °C to a vigorously stirred solution 
of 31 (0.1 g, 0.23 mmol) in dry pyridine (3 ml). The mixture was allowed to attain ambient 
temperature and stirring was continued overnight. TLC (in EtOAc – MeOH 5:1 with 1% 
NEt3) showed then that the reaction was complete. Excess of Ac2O was then destroyed by 
addition of methanol (50 µl) at 0 °C and stirring was continued for additional 30 min. The 
mixture was poured into iced water and the aqueous phase was extracted with CH2Cl2 (3 × 
10 ml). The combined organic phases were dried and concentrated. Chromatography (EtOAc 
– MeOH 10:1) gave the compound 32. 
Yield:   87 mg (73%), white amorphous solid 
[α]
D
23
:  +37.3 (c 1.0, CHCl3) 
mp:  149–156 °C 
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Rf:  0.34 (EtOAc:MeOH 10:1) 
1H NMR (250.13 MHz, CDCl3) 2 diastereomers: δ 0.86–1.10 [m, 28H, 4 x CH(CH3)2], 
1.52–1.72 (m, 1H, H-3a), 1.76–1.92 (m, 2H, H-3b, H-2'a), 1.95, 1.97 (2 x s, 6H, 2 x COCH3) 
2.04–2.20 (m, 1H, H-2'b), 3.24–3.55 (m, 1H, H-1), 3.64–3.71 (m, 1H, H-4'), 3.69–3.83 (m, 
1H, H-5'a)  3.94–4.08 (m, 2H, H-5'b, H-2), 4.08–4.30 (m, 1H, H-1'), 4.32–4.42 (m, 1H, H-
3'), 6.39, 7.02 (2 x d, 1H, NH-2), 6.54–6.67 (m, 1H, NH-1). 
13C NMR (62.89 MHz, CDCl3) 2 diastereomers: δ 12.50, 12.53, 12.76, 12.92, 13.24, 
13.28, 13.44, 13.48 [4 x CH(CH3)2], 16.92, 17.00, 17.06, 17.21, 17.34, 17.36, 17.45, 17.52 
[4 x CH(CH3)2], 23.15, 23.19, 23.44 (2 x COCH3), 37.64 (2) (C-3), 40.30, 40.62 (C-2'), 
44.20, 45.25 (C-1), 49.35, 49.39 (C-2), 62.44, 63.44 (C-5'), 71.33, 72.82 (C-3'), 74.88, 75.60 
(C-1'), 85.78, 86.22 (C-4'), 170.79, 171.03, 171.47 (2 x COCH3). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C24H48N2O6Si2 [M+H]
+: 517.31237, found 
517.31269; calcd for C24H48N2O6Si2 [M+Na]
+: 539.29431, found 539.29417. 
C24H48N2O6Si2 (516.83) calcd: C 55.78 H 9.36 N 5.42 
 found: C 55.72 H 9.21 N 5.29 
4.2.33 N,N'-(3-((2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl) 
propane-1,2-diyl)diacetamide (33)  
A solution of tetra-n-butylammonium fluoride trihydrate (70 mg, 0.27 mmol) in dry acetone 
(1 ml) was added dropwise at ambient temperature to a solution of 32 (0.1 g, 0.2 mmol) in 
dry acetone (10 ml). The reaction mixture was stirred for 1.5 h at ambient temperature (mon-
itored by TLC in EtOAc – MeOH 5:1) and then concentrated. Chromatography (EtOAc – 
MeOH 1:1) afforded compound 33. 
Yield:  46 mg (87%), colorless syrup 
[α]
D
23
:  +12.6 (c 1.0, MeOH) 
Rf:  0.3 (EtOAc:MeOH 1:1) 
1H NMR (500.13 MHz, MeOD, 2 diastereomers): δ 1.68–1.83 (m, 3H, H-3, H-2'a), 1.92–
2.02 (m, 1H, H-2'b), 1.98 (s, 6H,2 x COCH3) 3.18–3.26, 3.38–3.45 (m, 2H, H-1), 3.53–3.62 
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(m, 2H, H-5')  3.77–3.81 (m, 1H, H-4'), 4.05–4.17 (m, 1H, H-2), 4.18–4.24 (m, 2H, H-1', H-
3'). 
13C NMR (125.76 MHz, MeOD, 2 diastereomers): δ 22.73, 22.75, 22.95, 23.00 (2 x 
COCH3), 38.75, 38.89 (C-3), 42.23, 42.39 (C-2'), 44.33, 44.50 (C-1), 48.91, 49.09 (C-2), 
64.12 (2) (C-5'), 74.07, 74.15 (C-3'), 76.91, 77.30 (C-1'), 88.79, 88.88 (C-4'), 173.36, 173.38, 
173.81, 173.82 (2 x COCH3). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C12H22N2O5 [M+H]
+: 275.15728, found 
275.15706. 
C12H22N2O5 (274.32) calcd: C 52.54 H 8.08 N 10.21 
 found: C 50.11 H 8.67 N 9.98 
4.2.34 N,N'-(3-((6aR,8S,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5, 
2,4] tri oxadisilocin-8-yl)propane-1,2-diyl)bis(1-phenylmethanimine) (34) 
A mixture of compound 31 (70 mg, 0.16 mmol), benzaldehyde (31 µl, 0.3 mmol), molecular 
sieve powder (15 mg, A3 and A4) in dry methanol (0.7 ml) was stirred for 36 h at ambient 
temperature. The solution was filtered and concentrated without further purification to give 
compound 34. 
Yield:   80 mg (81%), brown-yellow syrup 
[α]
D
24
:  –13.9 (c 1.0, CHCl3) 
Rf:  0.31 (PE:EtOAc 10:1) 
1H NMR (300.13 MHz, CDCl3) 2 diastereomers: δ 0.84–1.21 [m, 28H, 4 x CH(CH3)2], 
1.43–2.36 (m, 4H, H-3, H-2'), 3.53–4.28 (m, 7H, H-1, H-1', H-2, H-5', H-4'), 4.28–4.50 (m, 
1H, H-3'), 6.62–7.95 (m, 10H, 10 x HPhenyl), 8.20, 8.24, 8.29 (3 x s, 3H, 2 x NCH). 
13C NMR (75.47 MHz, CDCl3) 2 diastereomers: δ 12.53, 12.89, 13.32, 13.42, [4 x 
CH(CH3)2], 16.93, 16.99, 17.10, 17.25, 17.38 (2), 17.52 [4 x CH(CH3)2], 39.92, 40.39 (C-
3), 40.49, 41.14 (C-2'), 64.12, 64.20 (C-5'), 66.16, 66.72 (C-1), 68.08, 68.25 (C-2), 73.98 (2) 
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(C-3'), 74.78, 75.18 (C-1'), 85.58, 85.60 (C-4'), 128.01, 128.03, 128.10, 128.43 (10 x CPhenyl), 
130.41, 130.46 (2), 130.50 (2 x CquartPhenyl), 161.37, 162.07, 162.53, 162.80 (2 x NCH). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C34H52N2O4Si2 [M+H]
+: 609.35384, found 
609.35413. 
C34H52N2O4Si2 (608.97) calcd: C 67.06 H 8.61 N 4.60 
 found: C 65.70 H 7.96 N 4.46 
4.2.35  5,7-dimethyl-2-(((6aR,8S,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-
f][1,3,5,2,4]trioxadisilocin-8-yl)methyl)-3,6-dihydro-2H-1,4-diazepine (35) 
A mixture of compound 31 (50 mg, 0.12 mmol) and acetylacetone (12.3 µl, 0.12 mmol) in 
dry ethanol (1 ml) was stirred for 24 h at ambient temperature (monitored by TLC in EtOAc 
– MeOH 1:1 with 1% NEt3). The solution was filtered and concentrated without other puri-
fication to give compound 35. 
Yield:   52 mg (91%), brown syrup 
[α]
D
24
:  –22.4 (c 1.0, CHCl3) 
Rf:  0.85 (EtOAc:MeOH 1:1) 
1H NMR (500.13 MHz, CDCl3) 2 diastereomers: δ 0.86–1.14 [m, 28H, 4 x CH(CH3)2], 
1.15–2.61 (m, 10H, H-3, H-2', 2 x CH3), 3.01–4.20 (m, 7H, H-1, H-2, H-1', H-4', H-5'), 4.25–
4.48 (m, 1H, H-3'), 4.90–5.04 (m, 2H, CH3CCH2CCH3). 
13C NMR (75.47 MHz, CDCl3) 2 diastereomers: δ 12.52 (2), 12.96, 13.45 [4 x CH(CH3)2], 
16.94, 17.01, 17.09, 17.25, 17.36 (3), 17.54 [4 x CH(CH3)2], 18.68, 18.94, 28.77, 28.85 (2 x 
CH3), 39.37, 40.07 (C-3), 40.54, 40.88 (C-2'), 48.87, 50.14 (C-1), 51.62, 51.75 (C-2), 63.75, 
64.30 (C-5'), 73.47, 73.92 (C-3'), 76.69, 77.20 (C-1'), 85.75, 86.73 (C-4'), 95.65, 95.90, 
95.00 (CH3CCH2CCH3), 162.46, 162.94, 163.11, 163.24, 163.54 (CH3CCH2CCH3). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C25H48N2O4Si2 [M+H]
+: 497.32254, found 
497.32250. 
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4.2.36 3-(((6aR,8S,9aS)-2,2,4,4-tetraisopropyltetrahydro-6H-furo[3,2-f][1,3,5,2,4]tri-
oxadisilocin-8-yl)methyl)-2,3,4,5-tetrahydrobenzo[f][1,4]diazocine-1,6-dione 
(36) 
Phthaloyl chloride (30 µl, 0.21 mmol) was added at 0 °C to a stirred solution of 31 
(68 mg, 0.16 mmol) in dry pyridine (2 ml). After stirring for 5 d at ambient temperature 
(monitored by TLC in EtOAc – MeOH 2:1) methanol (50 µl) was added and stirring was 
continued for additional 5 min. The mixture was poured into iced water and the aqueous 
phase was extracted with CH2Cl2 (5 × 10 ml). The combined organic phases were succes-
sively washed with aq 15% NaHSO4 (10 ml), ice water (10 ml), and sat aq NaHCO3 solution 
(10 ml), then dried and concentrated. Chromatography (EtOAc – MeOH 2:1) gave the com-
pound 36. 
Yield:   50 mg (57%), brown syrup 
[α]
D
24
:  –16.2 (c 1.0, CHCl3) 
Rf:  0.9 (EtOAc:MeOH 2:1) 
1H NMR (500.13 MHz, CDCl3) 2 diastereomers: δ 0.72–1.18 [m, 28H, 4 x CH(CH3)2], 
1.19–2.50 (m, 4H, H-3, H-2'), 3.05–5.06 (m, 8H, H-1, H-2, H-1', H-3', H-4', H-5'), 7.27–8.04 
(m, 4H, 4 x HPhenyl). 
13C NMR (125.76 MHz, CDCl3) 2 diastereomers: δ 12.57, 12.97, 13.40, 13.50 [4 x 
CH(CH3)2], 14.15 (2) (C-2), 16.97, 17.05, 17.14, 17.30, 17.38, 17.42 (2), 17.55 [4 x 
CH(CH3)2], 19.06 (2) (C-1), 37.74 (2) (C-3), 40.62 (2) (C-2'), 64.18 (2) (C-5'), 74.01 (2) (C-
3'), 77.69 (2) (C-1'), 85.95 (2) (C-4'), 123.30, 132.03, 132.30, 133.93 (4 x CPhenyl), 168.70, 
168.92 (2 x CquartPhenyl). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C28H46N2O6Si2 [M+H]
+: 563.29672, found 
C25H48N2O4Si2 (496.84) calcd: C 60.44 H 9.74 N 5.64 
 found: C 60.32 H 9.78 N 5.41 
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563.29682; calcd for C28H46N2O6Si2 [M+Na]
+: 585.27866, found 585.27825. 
C28H46N2O6Si2 (562.85) calcd: C 59.75 H 8.24 N 4.98 
 found: C 59.59 H 8.13 N 5.06 
4.2.37 (2R,3S,5S)-5-(2,3-diazidopropyl)-2-(hydroxymethyl)tetrahydrofuran-3-ol (37)  
A solution of tetra-n-butylammonium fluoride trihydrate (0.6 g, 2 mmol) in dry acetone (10 
ml) was added dropwise at ambient temperature to a solution of 29 (1 g, 2.1 mmol) in dry 
acetone (10 ml). The reaction mixture was stirred for 2 h at ambient temperature (monitored 
by TLC in EtOAc – Tol 1:1) and then concentrated. Chromatography (EtOAc) afforded 
compound 37. 
Yield:  430 mg (86%), light-yellow syrup 
[α]
D
24
:  –14.9 (c 1.0, CHCl3) 
Rf:  0.3 (EtOAc) 
1H NMR (300.13 MHz, CDCl3, 2 diastereomers): δ 1.62–1.87 (m, 3H, H-3, H-2'a), 1.99–
2.06 (m, 1H, H-2'b), 2.11 (br. s, 1H, OH-5'), 2.16 (br. s, 1H, OH-3'), 3.37–3.54 (m, 2H, H-
1), 3.61–3.80 (m, 3H, H-2, H-5'), 3.82–3.89 (m, 1H, H-4'), 4.19–4.36 (m, 2H, H-1', H-3'). 
13C NMR (75.47 MHz, CDCl3, 2 diastereomers): δ 36.9, 37.6 (C-3), 41.9 (2) (C-2'), 54.3, 
55.1 (C-1), 59.4, 59.6 (C-2) 63.1 (2) (C-5'), 73.2, 73.3 (C-3'), 75.1 (2) (C-1'), 87.0, 87.2 (C-
4'). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C8H14N6O3 [M+Na]
+: 265.10196, found 
265.10229. 
C8H14N6O3 (242.24) calcd: C 39.67 H 5.83 N 34.69 
 found: C 39.60 H 6.03 N 34.21 
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4.2.38 (2R,3S,5S)-5-(2,3-diazidopropyl)-2-((pivaloyloxy)methyl)tetrahydrofuran-3-yl 
pivalate (38)  
Pivaloyl chloride (2.5 ml, 0.02 mmol) and 4-(dimethylamino)pyridine (20 mg, 0.16 mmol) 
was added to a solution of 37 (90 mg, 0.4 mmol) in dry pyridine (5 ml). The reaction mixture 
was stirred for 2.5 h at ambient temperature (monitored by TLC in Tol – EtOAc 3:1) and 
then the mixture was concentrated and finally diluted with sat aq NaHCO3 solution (10 ml). 
The aqueous phase was extracted with CH2Cl2 (4 x 20 ml), dried and concentrated. Chroma-
tography (petroleum ether – EtOAc 9:1) afforded compound 38. 
Yield:  138 mg (90%), colorless syrup 
[α]
D
22
:  +26.3 (c 1.0, CH2Cl2) 
Rf:  0.35 (PE:EtOAc 9:1) 
1H NMR (300.13 MHz, CDCl3, 2 diastereomers): δ 1.20, 1.21 [m, 18H, 2 x C(CH3)3],  
1.57–1.95 (m, 3H, H-3, H-2'a), 2.04–2.10 (m, 1H, H-2'b), 3.32–3.55 (m, 2H, H-1), 3.67–
3.80 (m, 1H, H-2), 4.03–4.07 (m, 1H, H-4'), 4.11–4.25 (m, 3H, H-1', H-5'), 5.10–5.12 (m, 
1H, H-3'). 
13C NMR (75.47 MHz, CDCl3, 2 diastereomers): δ 27.0, 27.2 [2 x COC(CH3)3],  36.6, 37.7 
(C-3), 38.6, 38.8 [2 x COC(CH3)3], 38.9, 38.9 (C-2'), 54.3, 55.3 (C-1), 59.2, 59.7 (C-2) 64.2 
(2) (C-5'), 75.3, 75.5 (C-1'), 75.9, 76.1 (C-3'), 82.7, 82.8 (C-4'), 178.0, 178.1 [2 x 
COC(CH3)3]. 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C18H30N6O5 [M+Na]
+: 433.21699, found 
433.21673. 
C18H30N6O5 (410.48) calcd: C 52.67 H 7.37 N 20.47 
 found: C 52.70 H 7.42 N 20.39 
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4.2.39 (2R,3S,5S)-5-(2,3-diaminopropyl)-2-((pivaloyloxy)methyl)tetrahydrofuran-3-yl 
pivalate (39)  
Palladium on carbon 10 wt. % (160 mg, 1.5 mmol was added to a stirred solution of 38 
(0.5 g, 1.2 mmol) in dry methanol (7 ml). After stirring for 24 h at ambient temperature 
(monitored by TLC in EtOAc – MeOH 10:1 with 1% NEt3). The solution was filtered and 
concentrated. Analytical sample of 39 was achieved by chromatography (EtOAc – MeOH 
1:1 with 1% NEt3). 
Yield:  393 mg (90%), light-yellow syrup 
[α]
D
23
:  +8.43 (c 1.0, MeOH) 
Rf:  0.1 (EtOAc:MeOH 3:1) 
1H NMR (500.13 MHz, MeOD, 2 diastereomers): δ 1.20, 1.21 [2 x s, 18H, 2 x C(CH3)3], 
1.49–1.89 (m, 3H, H-3, H-2'a), 2.05–2.12 (m, 1H, H-2'b), 2.53–2.60 (m, 1H, H-1a), 2.69–
2.77 (m, 1H, H-1b), 2.92–2.96 (m, 1H, H-2), 3.99–4.03 (m, 1H, H-4'), 4.14–4.28 (m, 3H, H-
1', H-5'), 5.07–5.10 (m, 1H, H-3'). 
13C NMR (125.76 MHz, MeOD, 2 diastereomers): δ 27.54, 27.76 [2 x COC(CH3)3], 39.73, 
40.00 [2 x COC(CH3)3], 40.03, 40.22 (C-2'), 40.77, 41.05 (C-3), 48.33, 48.60 (C-1), 51.94, 
53.28 (C-2), 65.62, 65.69 (C-5'), 77.43, 77.67 (C-3'), 77.81, 79.47 (C-1'), 84.28, 84.49 (C-
4'), 179.65, 179.82 [2 x COC(CH3)3]. 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C18H34N2O5 [M+H]
+: 359.25405, found 
359.25421; calcd for C18H34N2O5 [M+Na]
+: 381.23599, found 381.23623. 
C18H34N2O5 (358.48) calcd: C 60.31 H 9.56 N 7.81 
 found: C 59.87 H 9.50 N 7.93 
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4.2.40 (2R,3S,5S)-5-(2,3-diacetamidopropyl)-2-((pivaloyloxy)methyl)tetrahydrofuran-
3-yl pivalate (40) 
Freshly distilled Ac2O (1.5 ml) was added dropwise at 0 °C to a vigorously stirred solution 
of 31 (140 mg, 0.3 mmol) in dry pyridine (3 ml). The mixture was allowed to attain ambient 
temperature and stirring was continued overnight (monitored by TLC in EtOAc – MeOH 5:1 
with 1% NEt3). Excess of Ac2O was then destroyed by addition of methanol (50 µl) at 0 °C 
and stirring was continued for additional 30 min at that temperature. The mixture was poured 
into iced water and the aqueous phase was extracted with CH2Cl2 (3 × 10 ml). The combined 
organic phases were dried and concentrated. Chromatography (EtOAc – MeOH 10:1) gave 
the compound 40. 
Yield:   108 mg (63%), colorless solid 
[α]
D
23
:  + 59.3 (c 1.0, CHCl3) 
Rf:  0.32 (EtOAc:MeOH 10:1) 
1H NMR (500.13 MHz, CDCl3, 2 diastereomers): δ 1.20, 1.21 [2 x s, 18H, 2 x C(CH3)3], 
1.41–2.15 (m, 10H, H-3, H-2', 2 x COCH3), 3.27–3.36, 3.58–3.67 (m, 2H, H-1), 3.91–4.03 
(m, 2H, H-2, H-4'), 4.07–4.67 (m, 3H, H-1', H-5'), 5.06–5.09 (m, 1H, H-3'), 6.40–6.42, 7.35–
7.36 (2 x d, 1H, NH-2), 6.63–6.70 (m, 1H, NH-1). 
13C NMR (125.76 MHz, CDCl3, 2 diastereomers): δ 22.87, 23.14, 23.41 (2) [2 x 
CO(CH3)], 26.99, 27.00, 27.22, 27.31 [2 x CO(CH3)3], 32.62, 36.85 (C-3), 38.55, 38.80 [2 
x Cquart] 38.90, 39.62 (C-2'), 43.49, 45.04 (C-1), 49.68, 50.60 (C-2), 63.50, 64.10 (C-5'), 
75.44, 75.52 (C-3'), 77.16, 77.20 (C-1'), 83.34, 84.45 (C-4'), 170.64, 171.10, 171.46, 172.65 
[2 x COC(CH3)], 178.08, 178.23, 178.38, 178.66 [2 x COC(CH3)3]. 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C22H38N2O7 [M+H]
+: 443.27518, found 
443.27547; calcd for C22H38N2O7 [M+Na]
+: 465.25712, found 465.25714. 
C22H38N2O7 (442.55) calcd: C 59.71 H 8.66 N 6.33 
 found: C 58.83 H 8.78 N 6.10 
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4.2.41 (2R,3S,5S)-5-(2,3-diazidopropyl)-2-((nonadecanoyloxy)methyl)tetrahydro 
furan-3-yl nonadecanoate (41)  
Stearoyl chloride (3 g, 10 mmol) and 4-(dimethylamino)pyridine (20 mg, 0.16 mmol) was 
added to a solution of 37 (160 mg, 0.66 mmol) in dry pyridine (20 ml). The reaction mixture 
was stirred for 2 h at ambient temperature (monitored by TLC in EtOAc) and then the mix-
ture was concentrated and finally diluted with sat aq NaHCO3 solution (10 ml). The aqueous 
phase was extracted with CH2Cl2 (5 x 20 ml), dried and concentrated. Chromatography (Tol 
– EtOAc 25:1) afforded compound 41. 
Yield:  426 mg (80%), white amorphous solid 
[α]
D
22
:  –2.6 (c 1.0, CHCl3) 
Rf:  0.25 (Tol:EtOAc 50:1) 
1H NMR (250.13 MHz, CDCl3, 2 diastereomers): δ 0.86–0.91 [m, 6H, 2 x 
CH2CH2(CH2)14CH3], 1.26 [br s, 56H, 2 x CH2CH2(CH2)14CH3], 1.58–1.69 [m, 4H, 2 x 
CH2CH2(CH2)14CH3], 1.75–1.92 (m, 3H, H-3, H-2'a), 2.09 (dd, 1H, 2J2'a,2'b =13.48 Hz, 3J2'b,3' 
= 4.81 Hz, H-2'b), 2.29–2.37 [m, 4H, 2 x CH2CH2(CH2)14CH3], 3.31–3.55 (m, 2H, H-1), 
3.66–3.81 (m, 1H, H-2), 4.03–4.11 (m, 1H, H-4'), 4.11–4.25 (m, 3H, H-1', H-5'), 5.9–5.13 
(m, 1H, H-3'). 
13C NMR (62.89 MHz, CDCl3, 2 diastereomers): δ 14.1 (2) [2 x CH2CH2(CH2)14CH3],  
22.7, 24.9, 24.9, 29.1, 29.1, 29.2, 29.3, 29.34, 29.5, 29.6, 29.7, 29.7 (2), 31.9, 34.2, 34.3 [2 
x CH2CH2(CH2)14CH3], 36.5, 37.7 (C-3), 38.6, 38.8 (C-2'), 54.3, 55.3 (C-1), 59.1, 59.6 (C-
2) 64.0 (2) (C-5'), 75.3, 75.5 (C-1'), 75.9, 76.0 (C-3'), 82.5, 82.6 (C-4'), 173.3, 173.4 [2 x 
COOCH2CH2(CH2)14CH3]. 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C46H86N6O5 [M+Na]
+: 797.62389, found 
797.62363. 
C46H86N6O5 (803.23) calcd: C 68.79 H 10.79 N 10.46 
 found: C 68.94 H 10.16 N 10.71 
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4.2.42 (2R,3S,5S)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(2,3-diazido 
propyl)tetrahydrofuran-3-ol (42)  
4,4′-Dimethoxytrityl chloride (850 mg, 2.5 mmol), 4-(dimethylamino)pyridine 
(30 mg, 0.25 mmol) and triethylamine (0.51 ml, 4 mmol)  was added to a solution of 37 (0.5 
g, 2.1 mmol) in dry DMF (15 ml). The reaction mixture was stirred for 24 h at ambient 
temperature (monitored by TLC in petroleum ether – EtOAc 1:1) and then was diluted with 
CH2Cl2 (15 ml). The solution was washed with iced water (10 ml) and sat aq NaCl (10 ml) 
dried, and concentrated.. Chromatography (petroleum ether – EtOAc 1:1) afforded com-
pound 42. 
Yield:  0.9 g (80%), yellow syrup 
[α]
D
22
:  –13.1 (c 1.0, CHCl3) 
Rf:  0.25 (Tol:EtOAc 50:1) 
1H NMR (500.13 MHz, CDCl3, 2 diastereomers): δ 1.53–1.71 [m, 1H, 3'-OH],  1.73–1.92 
(m, 3H, H-3, H-2'a), 1.97–2.04 (m, 1H, H-2'b), 3.10–3.13 (m, 1H, H-5'a), 3.23–3.26 
(m, 1H, H-5'b), 3.39–3.53 (m, 2H, H-1), 3.67–3.75 (m, 1H, H-2), 3.80 (s, 6H, CH3-O), 3.89–
3.92 (m, 1H, H-4'), 4.21–4.31 (m, 1H, H-1'), 4.32–4.36 (m, 1H, H-3'), 6.83–6.85, 7.16–7.25, 
7.28-7.34, 7.43–7.46 (m, 13H, Aryl-DMTr). 
13C NMR (125.76 MHz, CDCl3, 2 diastereomers): δ 31.1 (C-3), 41.1 (C-2'), 54.3 (C-1), 
55.2 (2 x CH3-O), 59.4 (C-2) 64.5 (C-5'), 74.4 (C-3'), 74.6 (C-1'), 86.1 (C-4'), 86.2 (C(Ph)3), 
113.1, 126.8, 127.8, 128.1, 129.1, 130.0, 136.0, 144.8, 158.5 (Aryl-DMTr). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C29H32N6O5 [M+Na]
+: 567.23264, found 
567.23318. 
C29H32N6O5 (544.61) calcd: C 63.96 H 5.92 N 15.43 
 found: C 68.94 H 10.16 N 10.71 
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4.2.43 ((2R,3S,5S)-2-((bis(4-methoxyphenyl)(phenyl)methoxy)methyl)-5-(2,3-diazido 
propyl)tetrahydrofuran-3-yl (2-cyanoethyl) diisopropylphosphoramidite (43)  
Compound 42 (125 mg, 0.23 mmol) was dried by co-evaporation with dry pyridine (3 x 
5 ml) and left under vacuum overnight. The residue was dissolved with dry CH2Cl2 (5 ml). 
2-cyanoethyl N,N-diisopropylchlorophosphoramidite (77 µl, 0.35 mmol) and diisopro-
pylethylamine (0.16 ml, 0.12 g, 0.92 mmol) were added under stirring. After stirring for 3 h 
at ambient temperature (monitored by TLC in petroleum ether – EtOAc 1:1 with 1% NEt3) 
the reaction mixture was diluted with CH2Cl2 (5 ml) and washed with sat aq NaHCO3 (6 ml) 
and sat aq NaCl (6 ml) dried and concentrated. Chromatography (petroleum ether – EtOAc 
2:1 with 1% NEt3) afforded compound 43. 
Yield:  103 mg (60%), yellow syrup 
[α]
D
23
:  +7.3 (c 1.0, CHCl3) 
Rf:  0.1 (PE:EtOAc 2:1 with 1% NEt3) 
1H NMR (500.13 MHz, CDCl3, 2 diastereomers): δ 0.91–1.58 [m, 12H, 2 x CH(CH3)2],  
1.61–1.95 (m, 3H, H-3, H-2'a), 2.08–2.42 (m, 1H, H-2'b), 2.47–2.97 (m, 2H, CH2CN), 3.00–
3.25 (m, 2H, H-5'), 3.26–3.67 (m, 4H, H-1, 2 x CH(CH3)2), 3.68–3.83 (m, 6H, CH3-O), 
3.85–4.46 (m, 5H, H-1', H-4', H-2, CH2OP),4.70–4.97 (m, 1H, H-3'), 6.71–6.85, 7.10–7.54, 
8.04–8.10 (m, 13H, Aryl-DMTr). 
13C NMR (125.76 MHz, CDCl3, 2 diastereomers): δ 20.03, 20.14 (CH2CN), 22.41, 22.58, 
22.85, 22.89, 22.94, 22.97 (2 x CH(CH3)2), 37.01 (C-3), 40.28 (C-2'), 45.25, 45.34 (2 x 
CH(CH3)2), 54.34 (C-1), 55.17 (2) (2 x CH3-O), 58.07, 58.16 (CH2OP), 59.44 (C-2) 64.15 
(C-5'), 77.20, 77.79 (C-3', C-1'), 86.06 (C-4'), 86.07 (C(Ph)3), 113.07 (Aryl-DMTr), 116.85 
(CN) 126.75, 127.75, 128.17, 129.17, 130.07 (2), 135.94, 136.14 (Aryl-DMTr). 
HRMS, ESI-TOF/MS positive (m/Q): calcd for C38H49N8O6P [M+H]
+: 745.35728, found 
745.35713. 
C38H49N8O6P (744.83) calcd: C 61.28 H 6.63 N 15.04 
 found: C 60.79 H 6.35 N 15.22 
3 
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